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Abstract
A systematic review and economic evaluation of exercise
referral schemes in primary care: a short report
Fiona Campbell,1* Mike Holmes,1 Emma Everson-Hock,1 Sarah Davis,1
Helen Buckley Woods,1 Nana Anokye,2 Paul Tappenden1
and Eva Kaltenthaler1
1Health Economics and Decision Science, School of Health and Related Research (ScHARR),
University of Sheffield, Sheffield, UK
2Health Economics Research Group (HERG), Brunel University, Uxbridge, UK
*Corresponding author f.campbell@sheffield.ac.uk
Background: It is estimated that only 39% of men and 29% of women in England achieve the levels of
physical activity that are recommended to protect health and prevent disease. One approach to addressing
this problem has been the development of exercise referral schemes (ERSs), in which health professionals
refer patients to external exercise providers. These schemes have been widely rolled out across the UK
despite concerns that they may not produce sustained changes in levels of physical activity and,
therefore, may not be cost-effective interventions. The evidence to determine clinical effectiveness and
cost-effectiveness was evaluated in 2009. This review seeks to update this earlier work by incorporating
new evidence and re-examining the cost-effectiveness.
Objectives: To assess the clinical effectiveness and cost-effectiveness of ERSs compared with usual care.
Design: Exhaustive searches of relevant electronic databases and journals were undertaken to identify new
studies evaluating ERSs using a randomised controlled trial (RCT) design. RCTs that incorporated a
qualitative evaluation of the intervention were identified in order to explore the barriers and facilitators to
the uptake of and adherence to ERSs. Data were extracted using a previously designed tool and study
quality assessed for potential bias. Where data could be pooled, meta-analyses were carried out.
Qualitative analysis was also undertaken using a thematic approach. The cost-effectiveness was evaluated
using a Markov structure which estimated the likelihood of becoming physically active and the subsequent
risk reduction on coronary heart disease (CHD), stroke and type 2 diabetes mellitus. The model adopts a
lifetime horizon, and a NHS and Personal Social Services perspective was taken with discounting at 1.5%
for both costs and benefits.
Results: The search identified one new RCT and one new qualitative study. The new data were pooled
with existing data from the 2011 review by Pavey et al. [Pavey TG, Anokye N, Taylor AH, Trueman P,
Moxham T, Fox KR, et al. The clinical effectiveness and cost-effectiveness of exercise referral schemes:
a systematic review and economic evaluation. Health Technol Assess 2011;15(44)] to give a total of
eight studies with 5190 participants. The proportion of individuals achieving 90–150 minutes of at least
moderate-intensity activity per week at 6–12 months’ follow-up was greater for ERSs than usual care
(relative risk 1.12; 95% confidence interval 1.04 to 1.20). Older patients and those referred for CHD risk
factors appeared to be more likely than others to increase their levels of physical activity. Qualitative
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evidence suggests that interventions enabling the development of social support networks are beneficial in
promoting uptake and adherence. Exercise referral gained 0.003 quality-adjusted life-years (QALYs) at an
additional cost of £225 per person. The estimated mean incremental cost-effectiveness ratio (ICER) in the
probabilistic sensitivity analysis was £76,276. In the univariate sensitivity analysis the results were very
sensitive (ICERs ranged from < £30,000 to > £100,000) to changes in the effect of ERSs on physical activity
uptake and the duration of the protective effects and the direct health-related quality-of-life gains
attributable to physical activity.
Conclusions: Exercise referral schemes result in a small improvement in the number of people who
increase their levels of physical activity. The cost-effectiveness analysis indicates that the ICER for ERSs
compared with usual care is around £76,000 per QALY, although the cost-effectiveness of ERSs is subject
to considerable uncertainty.
Study registration: This study is registered as PROSPERO CRD42013005200.
Funding: National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Exercise referral schemes (ERSs) are schemes in which health professionals refer patients to externalexercise providers to increase their physical activity to recommended levels. These schemes have been
widely rolled out across the UK, despite concerns that they may not produce sustained changes.
We combined data from eight randomised controlled trials to examine the effectiveness of ERSs. We found
that, compared with usual care, ERSs results in a small increase in the number of people who report that
they achieve the recommended level of physical activity. Referral to an ERS did not lead to changes in
objective measures of health such as weight or blood pressure.
Based on the experiences of those involved in the trials (those referred and those providing ERSs), people
who lacked their own transport or who lived in more deprived neighbourhoods were less likely to take up
a referral to an ERS, and people who had a history of being more physically active, who were referred for
coronary heart disease risk factors or who were older appeared to be more likely to increase their levels of
physical activity.
We found that the cost savings and health benefits attributable to reducing long-term risk stroke, type 2
diabetes mellitus and coronary heart disease through ERSs were small, although there may be some
immediate short-term health gain associated with becoming physically active. Overall, the upfront costs of
providing ERSs outweigh the benefits, although there was a large amount of uncertainty in our estimates
of the health benefits.
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Scientific summary
Background
Clinical effectiveness
There is a considerable body of evidence demonstrating the benefits of physical activity in terms of both
treating and preventing diseases. Current recommendations suggest that adults should undertake at least
150 minutes of moderate-intensity activity each week; however, according to the 2008 Health Survey
for England (Health Survey for England. Health Survey for England – 2008: Physical Activity and Fitness.
Leeds: Health and Social Care Information Centre; 2009) only 39% of men and 29% of women achieved
these levels.
Interventions to promote increased levels of physical activity require a wide variety of approaches, with
each facilitating small increments in behaviour change. These may include interventions targeted at the
population level, such as changes in the environment, as well as interventions targeted at the individual
level, such as brief advice delivered in primary care. Physical activity can be promoted in primary care in
different ways, including delivery of advice, provision of written materials and referral to an exercise
programme. The UK has seen an expansion in exercise referral schemes (ERSs) over the past two decades,
but there are concerns that these might not produce sustained changes in physical activity beyond the
typical programme length of 12 weeks. In 2006, the UK National Institute for Health and Care Excellence
(NICE) advised that there was insufficient evidence to recommend the use of ERSs to promote physical
activity other than as part of research studies where their effectiveness can be evaluated. Despite this
recommendation, the schemes are still widely used.
The NICE guidance Four commonly used methods to increase physical activity: brief interventions in
primary care, exercise referral schemes, pedometers and community-based walking and cycling (London:
NICE; 2006), which included guidance for ERSs, drew on a review of evidence which included four
randomised controlled trials (RCTs). An additional four studies have been included in the more recent
Pavey et al. review [Pavey TG, Anokye N, Taylor AH, Trueman P, Moxham T, Fox KR, et al. The clinical
effectiveness and cost-effectiveness, of exercise referral scheme: a systematic review and economic
evaluation. Health Technol Assess 2011;15(44)], three of which have been published since 2006.
The scope for this systematic review was to be an update of the Pavey et al. systematic review of the
evidence. However, this update is more limited than Pavey et al. owing to the time and resource
constraints of this project. In this update we have not included observational studies to explore issues of
adherence and uptake, but we have used the data from the included RCTs and explored explanations
given within the papers themselves. We have done this by qualitatively analysing the discussion and
conclusion sections of the included trials and, additionally, we identified qualitative studies undertaken as
part of a mixed-methods analysis of exercise referral.
Cost-effectiveness
In 2011, Anokye et al. (Anokye NK, Trueman P, Green C, Pavey TG, Hillsdon M, Taylor RS, et al. The
cost-effectiveness of exercise referral schemes. BMC Public Health 2011;11:954) published the results of
a cost-effectiveness model of ERSs based on data from a systematic review of the effectiveness of ERSs
by Pavey et al. They concluded that ERSs are associated with a modest increase in lifetime costs and
benefits and that the cost-effectiveness of ERSs is highly sensitive to small changes in the effectiveness
and cost of ERSs and is subject to some significant uncertainty, mainly because of limitations in the clinical
effectiveness evidence base.
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This model was later amended to inform the NICE public health appraisal of brief advice in primary care to
promote physical activity (PH44; Anokye et al. National Institute for Health and Clinical Excellence Public
Health Intervention Guidance on Physical Activity – Brief Advice for Adults in Primary Care: Economic
Analysis. London: NICE; 2012).
The scope for the economic analysis of ERSs for this brief report was to update the Anokye et al. (Anokye N,
Jones T, Fox-Rushby J. National Institute for Health and Clinical Excellence Public Health Intervention
Guidance Physical Activity: Brief Advice for Adults in Primary Care: Component 2 Economic Analysis. Review
of Economic Evidence. London: NICE; 2012) brief advice model with evidence from an updated systematic
review on the effectiveness of ERSs and to update the costs.
Objectives
To undertake a systematic review to re-assess the evidence for ERSs in order to determine clinical
effectiveness and estimate cost-effectiveness using a previously developed Markov model.
Methods
Clinical effectiveness
The search strategies used in the Pavey et al. systematic review of the evidence were used in this review.
Searches were limited by English language and a publication date of October 2009 to May/June 2013.
SPORTDiscus was not available to the research team, so Scopus (via Elsevier) was used, and the stage 1
search was conducted in this data source. Key sports and exercise science journals have been covered, as they
are indexed in one or more of the databases listed: MEDLINE and MEDLINE In-Process & Other Non-Indexed
Citations (via Ovid); EMBASE (via OvidSP); PsycINFO (via OvidSP); Scopus (via Elsevier); The Cochrane Library,
including the Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled
Trials (CENTRAL), NHS Health Technology Assessment (HTA) Database, NHS Economic Evaluation Database
(NHS EED), Database of Abstracts of Reviews of Effects (DARE); Science Citation Index and proceedings
and Social Science Citation Index and proceedings (via Web of Science Thomson Institute for Scientific
Information), UK Clinical Research Network Study Portfolio database; Current Controlled Trials; and Clinical
Trials.gov. The Journal of Aging and Physical Activity was found not to be indexed in the databases searched,
hence this journal was hand-searched by scanning the electronic table of contents available at http://journals.
humankinetics.com/japa-contents (2009–current and in-press articles as of September 2013).
Inclusion/exclusion criteria
Population
Any adult (aged 18 years or over) with or without a medical diagnosis and deemed appropriate for ERSs.
Interventions
The ERS exercise/physical activity programme is required to be more intensive than simple advice and
needs to include one or a combination of: counselling (face to face or via telephone); written materials;
supervised exercise training.
Comparators
Any control, for example usual (brief) physical activity advice, no intervention, attention control or
alternative forms of ERSs.
Outcomes
Physical activity, physical fitness, health outcomes, adverse events and uptake and adherence to ERSs.
SCIENTIFIC SUMMARY
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Study design
Any new RCT evidence, identified in searches of electronic databases published from October 2009 to
May/June 2013. We also included any qualitative studies (sibling studies that were done alongside the RCT
as part of a mixed-methods study).
Titles and abstracts were examined for inclusion by two reviewers independently. Disagreement was
resolved by consensus. Data were extracted and the data extraction tool was modelled on that used in the
Pavey et al. review. The Cochrane risk-of-bias tool was used to assess study quality.
Data from new studies published since 2009 were tabulated and discussed in a narrative review. The data
from studies already identified and analysed by Pavey et al. were used as published, and data from new
studies were integrated with them. Meta-analyses were used to estimate a summary measure of effect on
relevant outcomes based on intention-to-treat (ITT) analyses. These meta-analyses used data published in
the Pavey et al. review, and new data were added.
In order to extend our understanding of the factors that predict uptake and adherence, we undertook a
qualitative thematic analysis of the discussion and conclusion sections of the included RCTs. The terms
‘adherence’ and ‘uptake’ can be used variably within the literature. ‘Uptake’ refers to initial attendance, take
up or enrolment. ‘Adherence’ describes the level and duration of participation, and the threshold for
determining adherence may vary in different studies (Tobi P, Estacio EV, Yu G, Renton A, Foster N. Who stays,
who drops out? Biosocial predictors of longer-term adherence in participants attending an exercise referral
scheme in the UK. BMC Public Health 2012;12:347). The results were described in a narrative, and a logic
model was used to explore and explain associations between multiple and varied barriers and facilitators to
uptake and adherence of ERSs.
Cost-effectiveness
The cost-effectiveness model used to inform NICE PH44 (Anokye N, Jones T, Fox-Rushby J. National Institute
for Health and Clinical Excellence Public Health Intervention Guidance Physical Activity: Brief Advice for Adults
in Primary Care: Component 2 Economic Analysis. Review of Economic Evidence. London: NICE; 2012) was
updated with evidence from the updated systematic review on the effectiveness of ERSs and the costs were
uplifted to 2013. The model has a Markov structure and considers a cohort of 100,000 individuals aged
50 years who present in a physically inactive state and are given a referral to a service designed to increase
physical activity that includes a physical activity or exercise programme compared with a control group
with no referral to an exercise service. The age of the population was selected to reflect the populations
enrolled in the studies providing evidence on the effectiveness of ERS. The model estimates the likelihood of
becoming physically active and the consequent risk reduction this has on coronary heart disease (CHD),
stroke and type 2 diabetes mellitus.
A lifetime horizon has been adopted to acknowledge the long-term benefits of physical activity. The
economic perspective of the model is the NHS and Personal and Social Services (PSS) in the UK. Costs and
health benefits were discounted at an annual rate of 1.5% as recommended by the NICE guide to the
methods of technology appraisal.
Results
Clinical effectiveness
Our search of electronic databases and searching relevant journals yielded 9627 titles, of which one
primary study was judged to meet the inclusion criteria. This study was a mixed-methods evaluation,
incorporating RCT and qualitative evidence, undertaken in Wales. It was larger than previous studies,
with 2160 participants. Earlier studies ranged in size from 52 to 943 participants. The total number of
participants in all eight studies was 5190. Three studies were judged to be at moderate overall risk of bias
and five to be at low overall risk of bias.
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Referral to ERS was in most instances made by the general practitioner. In four of the studies, referral
was made because of an individual’s health risk that could be attenuated by increased levels of physical
activity, most commonly risk of CHD. In the other four studies, patients were referred on the basis of being
sedentary. Uptake, that is, the initial attendance, take up or enrolment following referral ranged from 35%
to 100% in the included studies. Adherence, that is, continued participation in the scheme, ranged from
21.5% to 86%. Some suggested barriers included the lack of a specific appointment at invitation. Lack of
private transport and deprivation were barriers to uptake and adherence. Older participants, and those
referred for non-weight-related CHD risk factors and those already moderately active at baseline, were
most likely to complete the programme.
The most consistently reported physical activity outcome across studies was the proportion of individual
achieving 90–150 minutes of at least moderate-intensity activity per week. When pooled across studies the
relative risk (RR) was 1.12 [95% confidence interval (CI) 1.04 to 1.20] of achieving this outcome with ERSs
compared with usual care at 6–12 months’ follow-up. These results show a decrease in the RR found by
Pavey et al. [RR 1.16 (95% CI 1.03 to 1.30)]. In the pooled ITT analyses, the proportion achieving the
physical activity threshold in the ERS group compared with usual care was RR 1.08 (95% CI 1.00 to 1.17).
This is also a reduction on the RR found by Pavey et al. (1.11, 95% CI 0.99 to 1.25).
When the total minutes of physical activity data were pooled, there was a significant increase in the
number of minutes of physical activity per week in the ERS group (mean difference 55.10 minutes,
(95% CI 18.47 to 91.73 minutes).
Examining subgroups, Murphy et al. (Murphy SM, Edwards RT, Williams N, Raisanen L, Moore G, Linck P,
et al. An evaluation of the effectiveness and cost effectiveness of the National Exercise Referral Scheme in
Wales, UK: a randomised controlled trial of a public health policy initiative. J Epidemiol Community Health
2012;66:745–53) reported that referral and participation in ERSs increased physical activity significantly for
those referred for CHD risk factors [odds ratio (OR) 1.29, 95% CI 1.04 to 1.60). However, among those
referred for mental health reasons, either solely or in combination with CHD, there was no difference in
physical activity between the ERS and normal-care participants at 12 months’ follow-up. The effect of
being in the ERS group on all referrals was an increase in levels of physical activity at 12 months, but this
finding was of borderline statistical significance (OR 1.19, 95% CI 0.99 to 1.43).
Cost-effectiveness
Exercise referral gained 0.003 quality-adjusted life-years (QALYs) at an additional cost of £225 per person.
The estimate for the mean incremental cost-effectiveness ratio (ICER) in the probabilistic sensitivity analysis
(PSA) was £76,276.
All of the PSA estimates show an incremental gain in both costs and QALYs; however, there is reasonable
uncertainty in the magnitude of that cost and QALY gain. The probability that ERSs are cost-effective at
a willingness-to-pay threshold of £30,000 per QALY gained is only 0.004.
In the univariate sensitivity analysis the results were very sensitive to increases in the effect of ERSs on
physical activity uptake, the protective effect of physical activity and the process utility gains (short-term
improvements in health-related quality of life) associated with increased physical activity. Small changes in
these parameters led to ICERs close to £30,000 per QALY gained. Conversely, sensitivity analyses that
applied more conservative assumptions on efficacy, duration of protective effect and process utility gain
resulted in ICERs over £100,000 per QALY.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxii
Discussion
Clinical effectiveness
There is evidence that ERSs can lead to improvements in self-reported levels of physical activity when
compared with receiving advice only. Increasing age is a factor that appears to support uptake and
adherence to ERSs, as is a greater level of physical activity at baseline. There is some evidence that, for
patients referred with CHD risk factors, there is more likelihood of increases in levels of physical activity.
It is not possible to identify what elements of the intervention support successful uptake of ERSs,
adherence to ERSs and long-term behaviour change. Qualitative evidence suggests that interventions that
enable the development of social support networks might be beneficial in promoting adherence and
long-term improvements in levels of physical activity. Practical factors, such as accessibility of leisure
centres, also play a part in uptake and adherence. ERSs seem to play a part in helping previously active
adults regain their levels of physical activity. They seem to be less effective in promoting uptake and
adherence among deprived populations.
Cost-effectiveness
There are several limitations to the analysis based on the updated model. The model only estimates the
impact of physical exercise on selected morbidities, and there may be others that would also benefit from
physical activity. Were these included in the model, the likely effect would be to lower the ICER, but the
magnitude is difficult to assess. The updated model also does not include the impact of adverse events
or injuries; however, available evidence suggests that these are minor and would have little effect on the
cost-effectiveness of ERSs.
A limitation in assessing subgroups (obesity, hypertension and depression) is that, with the exception of
the depression subgroup, the efficacy of ERSs is assumed to be the same as for the whole inactive
population. The model also assumes that the starting utility for these subgroups is the same as for the
general population. Were the utility to be lower it may lower the incremental QALY gains, resulting in a
higher ICER.
We were unable to assess whether or not less-intensive ERS could be effective at a lower cost and,
therefore, be cost-effective. The sensitivity analysis indicated that schemes would need a 60% reduction in
costs to achieve an ICER below £30,000 per QALY gained. However, less-intensive schemes may be less
effective and so data on both effectiveness and costs would be required to assess cost-effectiveness.
The results are very sensitive to small changes in some of the model parameters. A relatively small increase
in the efficacy of ERS or a 3-year increase in the length of the process utility gains both lead to ICERs that
are below £30,000 per QALY gained. In contrast, removing the process utility attributed to ERS results in
an ICER in excess of £180,000 per QALY gained, and using efficacy data from the ITT analysis, which
provides a more conservative estimate of effectiveness (RR 1.08, 95% CI 1.00 to 1.17), resulted in an ICER
of around £114,000.
The model oversimplifies the clinical situation because it does not recognise that more than one of the
three conditions can be present in the same individual and also that the presence of one comorbidity may
impact the likelihood of experiencing another. We are constrained here to using an existing economic
model in which type 2 diabetes mellitus, CHD and stroke are treated as mutually exclusive conditions. Also,
the model does not account for the fact that stroke patients are at a higher risk of having recurrent strokes
and, thus, the utility loss and additional costs associated with this are not taken into account. The impact
of these limitations on the cost-effectiveness of ERSs is difficult to estimate. It also excludes any long-term
benefits of physical activity that fall outside these three conditions.
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Conclusions
Our analysis indicates that the ICER for ERS compared with usual care is around £76,000 per QALY,
although the cost-effectiveness of ERSs is subject to considerable uncertainty and is particularly sensitive to
the assumptions made regarding the effectiveness of ERSs in increasing physical activity and the size and
duration of process utility gains.
Study registration
This study is registered as PROSPERO CRD42013005200.
Source of funding
National Institute for Health Research Health Technology Assessment programme.
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Chapter 1 Background
Description of health problem
There is a considerable body of evidence demonstrating the benefits of physical activity, in terms of both
treating and preventing diseases including coronary heart disease (CHD), stroke, type 2 diabetes mellitus,
chronic back pain, osteoporosis, cancers, depression and dementia.1,2 Current recommendations from the
Department of Health1 suggest that adults should undertake at least 150 minutes of moderate-intensity
activity each week (in the form of at least 30 minutes of activity on at least 5 days a week, which can be
split into three 10 minutes bouts in the same day); however, according to the 2008 Health Survey for
England, only 39% of men and 29% of women achieved these levels.3
Interventions to promote increased levels of physical activity require a wide variety of approaches, with
each facilitating small increments in behaviour change.4 These may include interventions targeted at the
population level, such as changes in the environment, as well as interventions targeted at the individual
level, such as brief advice delivered in primary care. Over the past 10 years or so, there has been a shift in
focus from promoting vigorous exercise to promoting moderate exercise, with more emphasis on lifestyle
activity, because of the expanding body of evidence suggesting that there may be greater population gains
through the least active becoming more active rather than moderately active people engaging in more
vigorous forms of activity.4
Description of technology under assessment
Primary care has been recognised as a potentially valuable setting for the promotion of physical activity in
those who might benefit most.5 One commonly used method to increase physical activity is the use of
exercise referral schemes (ERSs). ERSs have seen considerable growth and are now the most common form
of physical activity intervention in primary care.6
Exercise referral is the practice of referring a person from primary care to a qualified exercise professional
who uses relevant medical information about the person to develop a tailored programme of physical
activity usually lasting from 10 to 12 weeks. In so doing, opportunities for exercise are provided and there
is an expectation that levels of physical activity will increase, leading to positive changes in health
behaviours over the long term. These types of schemes usually rely on a partnership between the local
authority, primary care trust and private leisure service providers.
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Chapter 2 Definition of the decision problem
S ince the early 1990s there has been a considerable growth in the number of ERSs in the UK.5 By 2005,89% of primary care organisations in England ran an ERS, making it one of the most common forms of
physical activity intervention in primary care.6
Five previous systematic reviews7–11 have been undertaken in this area exploring the effectiveness of ERSs.
There was a lack of consistency in the included studies in each of these reviews, revealing a different
understanding and interpretation of ERSs between authors. Despite these varying definitions, these
previous systematic reviews conclude that ERSs have a small effect in increasing physical activity in the
short term, with little or no evidence of long-term sustainability (i.e. 12 months or longer). There was
also evidence of a reduced level of depression for participants given exercise referral compared with
usual care.11 However, owing to the considerable uncertainty surrounding the clinical effectiveness and
cost-effectiveness of ERS, in 2006, the National Institute for Health and Care Excellence (NICE) Public
Health Intervention programme determined that there was insufficient evidence to recommend the use
of ERSs as an intervention, other than as part of research studies in which their effectiveness could
be evaluated.
The NICE guidance Four commonly used methods to increase physical activity: brief interventions in
primary care, exercise referral schemes, pedometers and community-based walking and cycling,9 which
included guidance for ERSs, drew on a review of evidence which included four randomised controlled trials
(RCTs).12–15 An additional four studies have been included in a more recent review11 and its update,33 three
of which have been published since 2006.16–18
Physical activity can be promoted in primary care in different ways, including through delivery of advice,
provision of written materials and referral to an exercise programme. The UK has seen an expansion in
ERSs since 1990,5 but there are concerns that this might not produce sustained change in physical activity
beyond the typical programme length of 12 weeks.19 In 2006, NICE20 advised that there was insufficient
evidence to recommend the use of ERSs to promote physical activity other than as part of research
studies where their effectiveness can be evaluated. Despite this recommendation, the schemes are still
widely used.
A model-based economic evaluation of ERSs concluded that the cost-effectiveness of an ERS is highly
sensitive to small changes in the effectiveness and cost of an ERS and is subject to significant uncertainty,
mainly as a result of limitations in the clinical effectiveness evidence base.21
Given the considerable public health benefits of increasing levels of physical activity, it is important that
any initiatives for its promotion are kept under consideration and review. Within this short report, newly
available effectiveness evidence will be used to update the existing knowledge base and inform NICE
guidance for ERSs referred from primary care. The report will address the question ‘what is the clinical
effectiveness and cost-effectiveness of ERS to promote physical activity?’ Key factors that will be addressed
will include an analysis of effects for those referred for particular clinical conditions, and an exploration of
subgroups for whom intervention effectiveness might have a greater effect than for others, including
differences between sexes and age groups. We shall also explore where there may be differences in
outcomes that relate to key elements of the intervention, such as frequency of contact with the exercise
service. The economic evaluation will also build on previous work to explore whether or not the
cost-effectiveness of ERSs differs for those referred for particular clinical conditions (hypertension, obesity
and depression).
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Report methods for synthesis of evidence of clinical effectiveness
This report will be an update of the Pavey et al.11 systematic review of the evidence; updated searches will
be carried out in order to identify new evidence. Any new evidence that is identified will be reviewed
systematically and the findings integrated with those of the existing review. The scope of the review will be
more limited than in Pavey et al.,11 owing to the time and resource constraints of this project. We will only
include RCTs and systematic reviews of RCTs to analyse effectiveness. We will use only the included RCTs
to explore issues of adherence and uptake further. We will do this in two ways: (1) we shall explore
adherence and uptake in the trials and (2) we shall examine explanations given within the papers by the
authors. This will be done by qualitatively analysing the discussion and conclusion sections of the included
trials as well as by extracting data on the numbers of participants who were included in the trials and the
drop-out rates. In addition, using the included RCTs, we shall identify qualitative studies undertaken as
part of a mixed-methods analysis of exercise referral.
Overall aims and objectives of assessment
l To identify any new research evidence that has become available since 2009 to inform the review of
effectiveness of ERSs.
l To update the Pavey et al.11 review with any additional evidence.
l To qualitatively analyse the discussion and conclusion sections of the included studies to identify
potential barriers and facilitators to the implementation, uptake and adherence to ERSs.
l To explore, where data allow, any characteristics of the intervention or the population that might
influence the effectiveness of the intervention.
l To update the cost-effectiveness evaluation with any new evidence that has become available.
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing effectiveness
Identification of studies
The search strategy comprised the following main elements:
l searching of electronic databases
l contact with experts in the field
l scrutiny of bibliographies of retrieved papers.
The search strategies used in the Pavey et al.11 systematic review of the evidence were used in this review.
These consisted of two search strategies (stage 1 and stage 2), details of which are included in Appendix 1
of this report. The stage 1 search was a focused phrase search, with stage 2 being a more sensitive search
combining the terms for exercise referral with study type and setting terms (primary care). Searches were
limited by English language and a publication date of October 2009 to current (8 May 2013 for stage 1
and 17 June 2014 for stage 2). SPORTDiscus was not available to the research team; therefore, Scopus via
Elsevier was used, and the stage 1 search was conducted in this data source. Key sports and exercise
science journals such as Medicine and Science in Sports and Exercise and International Journal of Sports
Psychology have been covered, as they are indexed in one or more of the databases listed below. The
Journal of Aging and Physical Activity was found not to be indexed in the databases searched, hence this
journal was hand-searched by scanning the electronic table of contents available at http://journals.
humankinetics.com/japa-contents (2009–current and in-press articles as of September 2013).
Sibling studies
In order to identify any sibling studies (qualitative studies conducted as part of a mixed-method evaluation of the
intervention), two searches were undertaken. First, the names of authors and project names of the included
trials papers were searched for in Google Scholar (Google, Mountain View, CA, USA). To augment this search,
citation searches of the included trials were undertaken in the Science Citation Index and proceedings and Social
Science Citation Index and proceedings [viaWeb of Science Thomson Institute for Scientific Information (ISI)].
The following electronic databases were searched: MEDLINE and MEDLINE In-Process & Other Non-Indexed
Citations (via Ovid); EMBASE (via OvidSP); PsycINFO (via OvidSP); Scopus (via Elsevier); The Cochrane Library,
including the Cochrane Database of Systematic Reviews (CDSR), Cochrane Central Register of Controlled
Trials (CENTRAL), NHS Health Technology Assessment (HTA) Database, NHS Economic Evaluation Database
(NHS EED), Database of Abstracts of Reviews of Effects (DARE); Science Citation Index and proceedings and
Social Science Citation Index and proceedings (via Web of Science Thomson ISI), UK Clinical Research
Network Study Portfolio (UKCRN) portfolio database; Current Controlled Trials; and ClinicalTrials.gov.
An example of the stage 1 and 2 search strategies is shown in Appendix 1.
Inclusion/exclusion criteria
Population
The population included any adult (aged 18 years or over) with or without a medical diagnosis and
deemed appropriate for ERSs.
Interventions
The ERS exercise/physical activity programme is required to be more intensive than simple advice and
needs to include one or a combination of: counselling (face to face or via telephone), written materials and
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supervised exercise training. Programmes or systems of exercise referral initiated in secondary or tertiary
care, such as conventional comprehensive cardiac or pulmonary rehabilitation programmes, were excluded.
We will exclude trials of exercise programmes for which individuals will be recruited from primary care, but
there was no clear statement of referral by a member of the primary care team.
Comparators
Comparators included any control, for example usual (brief) physical activity advice, no intervention,
attention control or alternative forms of ERSs.
Outcomes
Outcomes included physical activity (self-reported or objectively monitored), physical fitness [e.g. maximal
oxygen uptake (VO2max), health outcomes (e.g. blood pressure), adverse events (e.g. musculoskeletal injury)] and
uptake and adherence to ERSs. We will also explore how patient characteristics, (age, sex and diagnosis) and
programme factors (e.g. length and intensity of the exercise programme) might influence the outcome of ERSs.
Study design
We included any new RCT evidence, identified in searches of electronic databases published from October
2009 to May/June 2013 (see Appendix 1). Data were extracted and the data extraction tool was modelled on
that used in the Pavey et al.11 review. We also searched for any systematic reviews of ERSs published from 2009
to May/June 2013. Their lists of included studies were hand-searched to identify any further relevant studies.
For any new RCTs that we identified, any qualitative data that have been reported as part of a mixed-methods
evaluation an ERS intervention were also included.
Any ongoing studies that we identify will also be reported. These would offer the most relevant insights
into the particular factors influencing the adherence and uptake of that particular ERS intervention.
Titles and abstracts were examined for inclusion by two reviewers independently. Disagreement was
resolved by consensus.
Exclusion criteria
l Animal models.
l Pre-clinical and biological studies.
l Narrative reviews, editorials, opinions.
l Non-English-language papers.
l Reports published as meeting abstracts only, in which insufficient methodological details are reported
to allow critical appraisal of study quality.
Quality assessment strategy
The Cochrane risk-of-bias tool was used to assess study quality.19 Consideration of study quality included
assessment of the following trials characteristics:
1. method of randomisation
2. allocation concealment
3. blinding
4. numbers of participants randomised, excluded and lost to follow-up.
5. whether or not intention-to-treat analysis has been performed
6. methods for handling missing data
7. baseline comparability between groups.
Methods of analysis/synthesis
Data from new studies published since 2009 were tabulated and discussed in a narrative review. The data
from studies already identified and analysed by Pavey et al.11 were used as published and data from new
studies were integrated with them.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Meta-analyses were used to estimate a summary measure of effect on relevant outcomes based on
intention-to-treat (ITT) analyses. These meta-analyses used data published in the Pavey et al.11 review and
new data were added.
Meta-analysis was carried out using fixed- and random-effects models, using Review Manager 12 software
(Thomson Reuters, Toronto, ON, Canada). Heterogeneity will be explored through consideration of the
study populations, methods and interventions, by visualisation of results and, in statistical terms, by
the chi-squared test for homogeneity and the I2 statistic.
In order to extend our understanding of the factors that predict uptake and adherence, we undertook a
qualitative thematic analysis of the discussion and conclusion sections of the included RCTs. This yielded
insights into the factors identified by the triallists that influenced variations in uptake or adherence. The
results will be described in a narrative, and a logic model used to explore and explain associations between
multiple and varied barriers and facilitators to uptake and adherence of ERSs.
Results
Quantity and quality of research available
Our search of electronic databases and relevant journals yielded 9627 titles, of which one primary study
was judged to meet the inclusion criteria. Figure 1 summarises the process of identifying the inclusion and
exclusion process. In two studies,22,23 additional data were supplied by the authors. One study,24 identified in
bibliographic searching, could not be retrieved. The main reasons for excluding studies included non-RCT
design (n= 44), participants recruited from primary care for inclusion in an exercise programme but without
referral from a health-care professional (n= 20), the intervention was a prescription to undertake exercise
but not a referral to a third-party exercise provider (n= 5), the population was not appropriate (n= 1),
participants were already part of an intervention prior to randomisation (n= 1) or randomisation occurred
prior to the baseline assessment (n= 1). Appendix 2 provides the full list of excluded studies. The included
studies are summarised in Table 1, which includes the studies incorporated in the Pavey et al. review.11
The new evidence is highlighted in bold type within the tables.
14,959 records identified through
database searching
286 additional records identified
through other sources
9871 records after duplicates removed
9871 records screened 9791 records excluded
80 full-text articles
assessed for eligibility
74 full-text articles
excluded with reasons
New studies included in review:
• 1 RCT (plus three sibling studies)
• 2 observational studies (uptake and
  adherence) 
FIGURE 1 Flow diagram demonstrating the process of identifying new studies for inclusion in the review.
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Characteristics of included studies
The characteristics of the included ERS studies are summarised in Table 2. All of the included studies were
RCTs. The Pavey et al.11 review included seven trials.12,15,18,26–28,31 The data from these studies are included in the
tables of this review, with new data emboldened. One additional study was identified (four publications).23,25,26,32
This study was a mixed-methods evaluation, incorporating RCT and qualitative evidence, undertaken in
Wales. It was larger than previous studies, with 2160 participants. The earlier studies ranged in size from 52 to
943 participants. The total number of participants in all eight studies was 5190.
The studies of Duda et al.17 and Gusi et al.28 used cluster allocation, with the other studies using individual-
level randomisation. Follow-up duration ranged from 2 to 12 months. The general practitioner (GP) was
the main referrer, usually using a bespoke referral form to a fitness or exercise instructor/officer. The
Murphy et al.23 study included referrals by health professionals working in a range of health-care settings.
Five studies12,15,26,23,28 compared ERSs with a usual-care group, which consisted of no exercise intervention
or simple advice on physical activity. Sorensen et al.27 compared ERSs with motivational counselling aimed
at increasing daily physical activity. The Isaacs et al. study18 also included an instructor-led walking
programme. The Duda et al. study17 compared two forms of ERSs, that is, standard ERS versus a combined
ERS plus self-determination theory (SDT)-based intervention.
Characteristics of participants
A total of 5190 participants were included in the eight trials.12,15,17,18,23,26–28 A summary of the characteristics
of participants is presented in Table 3. All of the studies recruited participants who were sedentary or who
were believed by their GP to be able to improve health by an increased physical activity level. They all also
excluded individuals who had poorly controlled hypertension, diabetes mellitus or heart disease. Gusi et al.28
also excluded those with severe obesity or major depression. Sorensen et al.27 included participants who
were willing to pay 750 Danish krone for the intervention.
The participants included in the Murphy et al. study23 shared a similar profile to those already included in
earlier studies. Most of those recruited were middle-aged white adults, with at least one medical condition,
who might benefit from an increased level of physical activity (Table 4). In the Murphy et al. study,23
72% of participants had CHD risk factors and 24% had mental health problems.
Characteristics of interventions
The characteristics of the interventions are summarised in Table 5. Interventions ran for between 10 weeks14,21,33
and 6 months28 and included instructor-led exercise classes or walks,28 some form of consultation aimed at
increasing activity22,33 or a combination of the two.14,17,21,23,34 The intervention by Sorensen et al.27 was based on
the transtheoretical model of behaviour change, which categorises people into stages of readiness for change
and postulates 10 experiential and behavioural processes of change, pro and con beliefs and self-efficacy beliefs
(beliefs in personal ability to carry out the behaviour in question).22 The Duda et al. intervention17 was based on
SDT, which emphasises the determinants and consequences of different reasons for behavioural engagement,
which vary in their degree of self-determination.23 The intervention aimed to promote autonomy support, which
is assumed to foster participants’ feelings of competence, autonomy and relatedness and, as a result, enhance
autonomous motivation for physical activity and associated mental health outcomes.17 The only study added
since the Pavey HTA,11 by Murphy et al.,23 was also the only study to explicitly use motivational interviewing.
However, fidelity to this intervention method during consultations was considered to be low. Motivational
interviewing is ‘a collaborative, person-centred form of guiding to elicit and strengthen motivation for change’.35
In those studies that held supervised exercise sessions or walks, the number of sessions per week varied
between one32 and three,28 with the most common being two sessions per week,14,17,21 although one study27 held
two sessions per week for the first 2 months and then one session per week for the following 2 months.
Supervised exercise sessions or walks lasted between 30–40 minutes12 and 1 hour.17,34 Two interventions were
group interventions28,34 and four were at group and/or individual levels.14,17,22,23
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Risk of bias
Table 6 summarises the risk of bias for each of the included studies. Most included a power calculation
and allocated participants using an appropriately generated random number sequence. However, the
reporting of concealment of trial group allocation was poor, although there was good evidence of
participant characteristics of intervention and control groups at baseline. Although blinding of participants
and intervention providers in these studies was not feasible, blinding of outcome assessment was possible.
Outcome blinding is particularly important in preventing assessment bias in the case of outcomes that
require observer judgement or involvement (e.g. blood pressure measurement or exercise testing). Two
studies17,23 reported outcome blinding. Recall Questionnaire was assessed via telephone to maintain
blinding. The reporting and handling of missing data were detailed for most studies, and all studies, except
one,12 reported the use of ITT analysis. The level of missing data at follow-up ranged across studies from
16.5% to 50%. Most studies used imputation methods (last observation carried forward or complete case
average values) to replace missing data values at follow-up. Overall, three studies12,15,26 were judged to be
at moderate overall risk of bias and five17,18,23,27,28 to be at low overall risk of bias.
Exercise referral scheme eligibility, uptake and adherence
There was a considerable range in the proportion of individuals randomised compared with those deemed
eligible (Table 7). In both the Sorensen et al.27 and Duda et al.17 studies, of those deemed eligible for ERSs,
a substantial number refused participation in the trial. In the Sorensen et al.27 study this low number may
be reflective of the 750 Danish krone payment by patients as part of a standard Danish Exercise on
Prescription. In the Duda et al.17 study, this may be related to the workload and training needs of the
health and fitness advisors at the time of recruitment.
TABLE 6 Summary of risk-of-bias assessment
Risk-of-bias criterion
Study and country
Taylor
et al.,12
UK
Stevens
et al.,26
UK
Harrison
et al.,15
UK
Isaacs
et al.,18
UK
Sorensen
et al.,27
Denmark
Gusi
et al.,28
Spain
Duda
et al.,17
UK
Murphy
et al.,23
UK
Power calculation reported? Yes Unclear Yes Yes Yes Yes Yes Yes
Method of random
sequence generation
described?
Yes Yes Yes Yes Yes Yes Yesa Yes
Method of allocation
concealment described?
Yesa Unclear Unclear Unclear Yes Yes Unclear Yes
Method of outcome
(assessment) blinding
described?
Unclear Unclear Unclear No Unclear Unclear Yes Yes
Were groups similar at
baseline?
Yes Yes Yes Yes Yes Yes Yes Yes
Was ITT analysis used? No Yes Yes Yes Yes Yes Yes Yes
Was there any statistical
handling of missing data?
Unclear Yes Unclear Yes Yes Yes Yes Yes
Were missing data (dropout
and loss to follow-up)
reported?
Yes Yes Yes Yes Yes Yes Yes Yes
a Pavey et al.11 retrieved data from author.
New evidence is highlighted in bold in the table.
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The terms ‘adherence’ and ‘uptake’ can be used variably within the literature. ‘Uptake’ refers to initial
attendance, take-up or enrolment. ‘Adherence’ describes the level and duration of participation, and the
threshold for determining adherence may vary in different studies.34
Rates of uptake varied in the included studies. Taylor et al.,12 Isaacs et al.,18 Sorensen et al.27 and Murphy
et al.23 reported uptake rates in excess of 85%, and in the Stevens et al. study26 only 126 (35%) of the
363 randomised to ERSs attended the first consultation. Stevens et al.26 discussed how the low uptake they
experienced may have been reflective of the nature of the invitation letter sent to participants and the
point of randomisation (pre-invitation letter). Furthermore, they hypothesise that a change in the format of
the letter (e.g. including a specific appointment date for the first ERS appointment) would have improved
participation. Uptake was not reported by Duda et al.17 or Gusi et al.28
Adherence was assessed differently between the trials, and levels of adherence also varied. Stevens et al.26
and Gusi et al.28 reported ERS programme completion rates of 25% and 86%, respectively. However,
these rates do not reflect the number of sessions attended, only those who attended a second
consultation26 or follow-up assessment.28
Sorensen et al.27 reported that an average of 18 out of a total of 24 ERS exercise sessions were attended
and 68% and 75% of participants attended the counselling sessions at 4 and 10 months, respectively. Both
Taylor et al.12 and Isaacs et al.18 provide a detailed description of ERS programme adherence. Taylor et al.12
reported 13% attending no exercise sessions and 28% attending 75–100% of exercise sessions, with an
average of 9.1 out of 20 prescribed exercise sessions attended. Isaacs et al.18 reported 7.6% attending no
exercise sessions and 42% attending 75–100% of exercise sessions in the leisure centre group. In the
walking group, 23.5% attended no exercise sessions, with 21.5% attending 75–100% of exercise sessions.
As shown in Table 8, there was no consistent difference in attendance rates between those in at-risk groups
TABLE 7 Summary of eligibility and uptake figures for included studies
Study Country
Number
deemed
eligible (n)
Total n
randomised
(%) ERS (n) Control (n)
ERS uptake,
n (%)
Taylor et al.12 UK 345 142 (41) 97 45 85 (88)
Stevens et al.26 UK 827 714 (86) 363 351 126 (35)
Harrison et al.15 UK 830 545 (66) 275 270 232 (84)
Isaacs et al.18 UK 1305 949 (73) 317 leisure centre,
315 walking
311 293 (92)
Sorensen et al.27 Denmark 327 52 (16) 28 24 28 (100)
Gusi et al.28 Spain 160 127 (79) 64 63 Not reported
Duda et al.17 UK 1683 347 (21) 184 163 Not reported
Murphy et al.23 UK 3286 2160 (66) 1080 1080 n= 919 (85)
New evidence is highlighted in bold in the table.
TABLE 8 Proportion of individuals by risk group with 75–100% ERS attendance rates
Study Country Smoking (%) Obesity (%) Hypertension (%) Overall (%)
Taylor et al.12 UK 12 28 23 28
Isaacs et al.,18 ERS group UK 45.5 38.8 46.1 42
Isaacs et al.,18 control walking group UK 26.3 18.7 22.9 21.5
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and the overall study population in the studies of Taylor et al.12 and Isaacs et al.18 In the Isaacs et al. study,18
the 60–69 years age group had the highest adherence in both the ERS (53.3%) and the walking (24.2%)
groups. There were no significant differences in attendance rate based on employment status, educational
level, socioeconomic status, ethnicity or relationship status. However, Murphy et al.23 did find differences
in uptake and adherence between participants from deprived and less-deprived areas. Adherence was
lower for those without access to private transport in both the ERS and walking groups. Harrison et al.15 and
Duda et al.17 did not provide information on participants’ adherence to the ERS intervention.
Murphy et al.23 found that participants already active at baseline were the most likely to enter the ERS, but
that they were also most likely to partially attend a programme. Men and younger participants were
slightly less likely to enter the scheme, and women were less likely to complete the programme.
Participants in the least-deprived areas were more likely to take up the scheme, although the differences in
adherence between the most- and least-deprived areas were smaller. Non-car owners were less likely to
take up the scheme or to adhere to it if they joined. Those referred for mental health reasons were more
likely not to enter the ERS, and only one in three mental health patients completed the programme.
In a univariate regression analysis of predictors of uptake and adherence, the only significant correlates of
uptake in the Murphy et al. study23 were car ownership and deprivation. Those in moderately deprived
areas were less likely to enter the ERS than those in the least-deprived areas. Car owners were significantly
more likely to enter the ERS than non-car owners. Older participants, those referred for non-weight-related
CHD risk factors, non-mental health patients and those already moderately active at baseline were most
likely to complete the programme.
In a multivariable regression analysis, the significant difference between low and medium deprivation areas
remains and car ownership remains predictive of uptake. Associations of CHD risk factors with adherence
become non-significant and associations of age and mental health status remain significant. Associations
of baseline activity with adherence are strengthened in the multivariable analysis, with the contrast
between inactive and moderately inactive participants becoming more significant (see Barriers and
facilitators of referral, uptake and adherence to exercise referral schemes for further discussion of factors
influencing uptake and adherence).
Assessment of effectiveness
Only Isaacs et al.18 reported all outcome domains applicable to this systematic review (Table 9). New data
added to the Pavey et al.11 review are emboldened within the tables.
Physical activity
All studies, with the exception of Gusi et al.,28 provided a measure of self-reported physical activity.
Self-reported measures included the validated 7-Day Physical Activity Recall (7-Day PAR) questionnaire12,23,26,27
and the validated Minnesota Leisure Time Activity questionnaire.18 None of the studies reported methods of
measuring physical activity using an objective method of measurement, and all relied on self-report tools.
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Exercise referral schemes versus usual care/advice only
The most consistently reported physical activity outcome across studies was the proportion of individuals
achieving 90–150 minutes of at least moderate-intensity activity per week. Data for this outcome in the
Murphy et al. study23 were supplied by the author (Professor Simon Murphy, Cardiff University, 2013,
personal communication). When pooled across studies the relative risk (RR) was 1.12 [95% confidence
interval (CI) 1.04 to 1.20] of achieving this outcome with ERS compared with usual care at 6–12 months’
follow-up (Figure 2). There was no evidence of heterogeneity in this analysis (I2 0%). This analysis
draws on data published by Pavey et al.11 Three studies12,15,23 reported this outcome based on the number
of individuals who were available at follow-up. These results show a decrease in the RR found by Pavey
et al.11 (RR 1.16, 95% CI 1.03 to 1.30). In order to assess the potential (attrition) bias in using completers,
the denominators of these three studies were adjusted to all individuals randomised in order to perform
an ITT analysis (Figure 3). It was assumed that all missing cases did not meet the physical activity
threshold. In the pooled ITT analyses, the proportion achieving the physical activity threshold in the ERS
group compared with usual care was RR 1.08 (95% CI 1.00 to 1.17). There was no evidence of
heterogeneity in this analysis (I2 0%). This is also a reduction on the RR found by Pavey et al.11 (RR 1.11,
95% CI 0.99 to 1.25).
Total minutes of physical activity were reported by Isaacs et al.18 and Murphy et al.23 When these data
were pooled, there was a significant increase in the number of minutes of physical activity per week in the
ERS group; mean difference 55.10 minutes (95% CI 18.47 to 91.73 minutes) (Figures 4–6).
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Exercise referral schemes versus alternative physical activity intervention
Sorensen et al.27 reported a higher level of energy expenditure with ERS than with physical activity
counselling. In contrast, the study by Isaacs et al.18 observed a higher level of physical activity (minutes of
total and moderate-intensity activity, energy expenditure) in those in the walking programme than in the
ERS group. When pooled across studies, there was no significant difference in the total amount of physical
or energy expenditure between ERSs and alternative physical activity interventions (Figures 7 and 8).
Exercise referral schemes versus a self-determination theory informed delivery of
exercise on referral
In the Duda et al. study,17 the proportion of patients achieving at least 150 minutes of moderate physical
activity per week increased in the standard ERS group from 27% at baseline to 63% at 3 months and
46% at 6 months. There were no significant differences in these proportions between the standard ERS
and a SDT-informed delivery of ERSs (Table 10).
Subgroup analysis exploring the impact of patient variables on effects of exercise
referral schemes on levels of physical activity
Pavey et al.11 reported the following analysis of subgroups within seven studies: Harrison et al.15 reported
no statistical significant interaction effects between the ERS effect and pre-specified baseline variables
(i.e. CHD risk factors, sex and age). Comparing high adherers (> 75% attendance at ERS) with low
adherers (< 75% attendance at ERS) in the Isaacs et al.18 study, 32 high adherers and 16 low adherers
were achieving > 150 minutes of moderate physical activity per week at 10 weeks. At 6 months, 41 high
adherers and 29 low adherers were achieving > 150 minutes of moderate physical activity per week.
However, these proportions were not significantly different. In the Duda et al. study,17 age, sex, deprivation
(Index of Multiple Deprivation score), ethnicity, depression at baseline and level of physical activity at
baseline were assessed by regression methods as predictors of physical activity at 6 months. Only physical
activity at baseline was associated with physical activity at 6 months’ follow-up (p< 0.001). Murphy et al.23
also found that effectiveness was highly dependent on adherence, with significantly greater differences
in all outcomes among those who completed the 16-week programme compared with those who
attended only partially or not at all.
Murphy et al.23 reported that referral and participation in ERSs increased physical activity significantly
for those referred for CHD risk factors [odds ratio (OR) 1.29, 95% CI 1.04 to 1.60]. However, among those
referred for mental health reasons, either solely or in combination with CHD, there was no difference in
physical activity between the ERSs and normal-care participants at 12 months’ follow-up. The effect of
being in the ERS group on all referrals was an increase in levels of physical activity at 12 months, but this
finding was of borderline statistical significance (OR 1.19, 95% CI 0.99 to 1.43).
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Physical fitness
No additional data were available for this outcome; the following results are taken from Pavey et al.11
The studies by Taylor et al.,12 Isaacs et al.18 and Sorensen et al.27 reported physical fitness outcomes
(Table 11).
Exercise referral schemes versus usual care
Taylor et al.12 reported a lower (more favourable) submaximal heart rate (at 150W) for ERS compared with
usual care. Isaacs et al.18 reported no significant differences in any of the physical fitness measures
(submaximal bike and shuttle walk, isometric knee strength, leg extension power) between the ERS and
usual-care groups at follow-up, except at 10 weeks for the submaximal bike ergometer test. Pooling of the
cardiorespiratory measures (mode: cycle ergometer or cycle/walking) showed no difference between ERSs
and usual care (Figure 9). There was considerable evidence of statistical heterogeneity.
Exercise referral schemes versus alternative physical activity intervention
Isaacs et al.18 and Sorensen et al.27 reported no significant differences in any of the physical fitness
measures between the ERS and the alternative physical activity intervention groups at follow-up
(see Figure 9).
Exercise referral schemes versus exercise referral scheme plus self-determination theory
The study of Duda et al.17 did not assess physical fitness.
Clinical factors
Five studies provided information on clinical outcomes, that is, CHD risk factors (Table 12), weight and
obesity measures (Table 13) and respiratory function (Table 14).
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Exercise referral schemes versus usual care
Taylor et al.12 reported percentage of body fat in ERS participants compared with usual care at follow-up
and found no statistically significant difference between the groups. Gusi et al.28 reported a lower body
mass index (BMI), with no other between-group differences in weight and body fat outcomes for the other
measured clinical factors (Figures 10 and 11). There was no significant difference in resting blood pressure,
serum lipids or respiratory function between ERSs and usual care at follow-up (Figures 12 and 13).
Exercise referral schemes versus alternative physical activity intervention
In both the studies by Isaacs et al.18 and Sorensen et al.27 there were no significant between-group
differences at follow-up in resting blood pressure (see Figures 10 and 11), BMI (see Figure 12), body fat
outcomes, serum lipids and respiratory function. The Sorensen et al. trial27 reported reduced levels of
glycosylated haemoglobin (HbA1c) in both the ERS group (mean –0.26%, 95% CI –0.79% to 0.27%) and
the physical activity counselling group (mean –0.23%, 95% CI –0.47% to 0.02%) at 4 months’ follow-up,
although there was no difference between groups.
Exercise referral schemes versus exercise referral scheme plus self-determination theory
Duda et al.17 reported no significant difference between standard ERS and ERS plus SDT in BMI or resting
blood pressure.
Psychological well-being
Four studies17,18,23,25,28 reported psychological well-being outcomes and the results are summarised in
Table 15.
TABLE 14 Summary of respiratory function outcomes in included ERS trials
Study and time
of follow-up
FEV : FVC ratio PEF
ERS, mean (SD) Usual care, mean (SD) ERS, mean (SD) Usual care, mean (SD)
ERS vs. usual care
Isaacs et al.18
10 weeksa 0.86 (0.0) 0.86 (0.06)b 417 (58) 409 (58)b
6 monthsa 0.86 (0.09) 0.86 (0.09)b 407 (115) 411 (117)b
ERS vs. alternative PA intervention
Isaacs et al.18
10 weeksa 0.86 (0.0) 0.85 (0.06)b 417 (58) 407 (61)b
6 monthsa 0.86 (0.09) 0.85 (0.09)b 407 (115) 416 (117)b
FEV, forced expiratory volume; FVC, forced vital capacity; PA, physical activity; PEF, peak expiratory flow;
SD, standard deviation.
a All randomised participants.
b Between-group difference not statistically significant at p-value≤ 0.05.
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Exercise referral schemes versus usual care
Taylor and Fox25 reported physical self-perceptions measures, with improvements shown in physical
self-worth, and perceptions of physical condition and physical health-collected physical self-perceptions
data, and reported significant differences favouring the ERS group compared with usual-care group at
16 and 37 weeks. Isaacs et al.18 reported no differences between the ERS and usual-care groups in
the anxiety and depression scores using the Hospital Anxiety Depression Scale (HADS) at 6 months. In the
Gusi et al. study,28 all measures [Geriatric Depression Scale, State Trait Anxiety Inventory and the anxiety/
depression subscale of the European Quality of Life-5 Dimensions (EQ-5D)] at 6 months were found to
favour ERS participants compared with those receiving the usual care. In the Murphy et al. study,23 in
participants who were referred for mental health reason or in combination with CHD, there were
significantly lower levels of anxiety (OR –1.56, 95% CI –2.75 to –0.38) and depression (OR –1.39, 95% CI
–2.60 to –0.18) but no effect on physical activity. Murphy et al.23 also found significant interactions with
sex for both mental health outcomes, with the beneficial effect of the intervention apparent only among
women. There was a suggestion that the intervention was more effective on mental health outcomes
among the youngest age group (18–44 years), although this was not statistically significant. Effects did not
vary significantly by deprivation status.
Pavey et al.33 in a review updating his earlier review,11 pooled HADS score data from Murphy et al.23 and
Gusi et al.28 (Figure 14). This showed a significant reduction in depression (standardised mean difference
–0.82, 95% CI –1.28 to –0.35) but not in anxiety (standardised mean difference –4.12, 95% CI –11.52 to
3.28) for ERSs compared with usual care.
Exercise referral schemes versus alternative physical activity intervention
Isaacs et al.18 reported no differences between the ERS and walking programme in anxiety or depression
outcomes at the 6-month follow-up.
Exercise referral schemes versus exercise referral scheme plus self-determination theory
Duda et al.17 reported no difference between groups in anxiety or depression outcomes at either the
3- or 6-month follow-up.
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Health-related quality of life
Five studies17,18,23,27,28 reported health-related quality of life (HRQoL), as summarised in Table 16.
Exercise referral schemes versus usual care
Isaacs et al.18 reported no differences between the ERS and usual-care groups at follow-up on the Short
Form questionnaire-36 items (SF-36) mental health scale. Gusi et al.28 observed higher EQ-5D scores in the
ERS group than in the usual-care group at 6 months. Murphy et al.23 also observed higher EQ-5D scores in
the ERS group than in the usual-care group at 12 months, but it was not statistically significant.
Exercise referral schemes versus alternative physical activity intervention
Isaacs et al.18 reported no differences between the ERS and walking groups at follow-up on the SF-36
mental health scale score. Similarly, Sorensen et al.27 found no differences in scores between the groups at
follow-up on the Short Form questionnaire-12 items (SF-12) items mental and physical scales.
Exercise referral schemes versus exercise referral scheme plus self-determination theory
Duda et al.17 reported no difference between groups in overall Dartmouth CO-OP (Primary Care Cooperative
Information Project) chart score, although there was a difference for the feelings subscale at 6 months in
favour of the alternative ERS group (not tabularised).
Patient satisfaction
Two studies15,18 reported patient satisfaction and results are summarised in Table 17.
Exercise referral schemes versus usual care
The Harrison et al. study15 reported that the ERS group participants were significantly more satisfied with
the information they received and felt they needed less information about physical activity compared
with the usual-care group. In the Taylor et al. study,12 comments about the concept of ERSs (measured at
8 weeks) identified that 50% of patients were positive, 35% had mixed feelings and 15% had only
negative comments. Negative comments included a long waiting time before introductory session, lack of
staff support, crowded facilities and inconvenient facility times.
Exercise referral schemes versus alternative physical activity intervention
In the Isaacs et al.18 study, there was no between-group difference in participant satisfaction with received
information or the need for additional information. In the ERS group, 97.8% felt better for taking part and
enjoyed the programme compared with the walking group, in which 93.8% felt better for taking part
and 95.2% enjoyed the programme.
Exercise referral schemes versus exercise referral scheme plus self-determination theory
Duda et al.17 did not assess participant satisfaction.
Adverse events
Although participation in ERSs has the potential to lead to negative events (e.g. an increase in exercise-related
musculoskeletal injuries or exercise-related cardiac complications), only the Isaacs et al.18 study assessed such
events. Using GP records, the authors assessed the change in consultations before and after ERSs. There was
evidence of a small increase in GP visits for falls and fractures in the ERSs and walking groups compared with
usual-care control after the start of the study (Table 18).
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TABLE 17 Summary of participant satisfaction in included ERS trials
Study
Satisfied with received information (%) Needed further information (%)
ERS, mean (SD) Usual care, mean (SD) ERS, mean (SD) Usual care, mean (SD)
ERS vs. usual care
Harrison et al.15
3 months 92 69a 43 54a
ERS vs. alternative PA intervention
Isaacs et al.18
10 weeks 97 96b 15 17b
PA, physical activity.
a Statistically significant at p-value≤ 0.05 (p-value calculated by authors of the present report).
b Difference not statistically significant at p-value≤ 0.0.
TABLE 18 Adverse events reported by the Isaacs et al.18 UK study (GP visits)
Adverse events Leisure centre Walking control Advice-only control
Visits for chest pain
12–6 months before start of study 1 (%) 3 7
6 months before start of study 3 (%) 4 7
Start of study to 6 months 2 (%) 9 7
6–12 months after start of study 10 (%) 4 –
Visits for aches/pains
12–6 months before start of study 64 48 56
6 months before start of study 62 53 55
Start of study to 6 months 52 42 44
6–12 months after start of study 63 44 –
Visits for sprains
12–6 months before start of study 2 2 7
6 months before start of study 3 6 2
Start of study to 6 months 1 4 6
6–12 months after start of study 2 0 –
Visits for falls
12–6 months before start of study 1 1 0
6 months before start of study 1 1 2
Start of study to 6 months 9 2 0
6–12 months after start of study 3 6 –
Visits for fractures
12–6 months before start of study 0 1 1
6 months before start of study 0 0 0
Start of study to 6 months 1 0 0
6–12 months after start of study 0 4 –
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Health-care utilisation
No studies reported hospitalisations, primary care visits or use of medication.
Intervention characteristics relating to effectiveness and adherence outcomes
Since the impact of ERSs on physical activity outcomes was not significant relative to control in most
studies, it is difficult to tease out the characteristics of effective interventions. The only study to find a
significant (albeit small) benefit of an ERS over and above brief advice on some physical activity outcomes
utilised a counselling intervention (three sessions) based on motivational interviewing plus access to
subsidised exercise classes for 16 weeks, compared with normal care and brief written information.23 The
duration of the scheme was slightly longer than most other interventions, and the components of the
scheme were similar to the other interventions, apart from the use of motivational interviewing as a tool in
exercise counselling (although fidelity was found to be poor). The comparison condition may have been
less intensive than comparison conditions in some other studies, and, interestingly, levels of adherence
were low. See Table 19 for a summary of the included studies intervention and control characteristics
relative to effectiveness and adherence. In addition, see Table 20 for further details of the components of
the ERS interventions.
DOI: 10.3310/hta19600 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 60
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Campbell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
45
TA
B
LE
19
C
o
m
p
ar
is
o
n
o
f
in
cl
u
d
ed
st
u
d
ie
s’
in
te
rv
en
ti
o
n
(a
n
d
co
n
tr
o
l)
ch
ar
ac
te
ri
st
ic
s
re
la
ti
ve
to
ef
fe
ct
iv
en
es
s
an
d
ad
h
er
en
ce
St
u
d
y
Sc
h
em
e
d
u
ra
ti
o
n
N
u
m
b
er
o
f
se
ss
io
n
s
p
er
w
ee
k
D
u
ra
ti
o
n
o
f
ex
er
ci
se
se
ss
io
n
s
G
ro
u
p
o
r
in
d
iv
id
u
al
C
o
m
p
o
n
en
ts
Th
eo
re
ti
ca
l
b
as
is
C
o
n
tr
o
lc
o
n
d
it
io
n
Fo
llo
w
-u
p
Ef
fe
ct
iv
en
es
s
A
d
h
er
en
ce
Ta
yl
or
et
al
.
19
98
12
/2
00
52
5
10
w
ee
ks
2
30
–
40
m
in
ut
es
G
ro
up
an
d/
or
in
di
vi
du
al
Ex
er
ci
se
pr
es
cr
ip
tio
n;
su
bs
id
is
ed
ex
er
ci
se
se
ss
io
ns
N
ot
re
po
rt
ed
H
EA
le
af
le
ts
on
pr
ev
en
tin
g
C
H
D
(b
ut
no
sp
ec
ifi
c
PA
ad
vi
ce
)
8,
16
,
26
an
d
37
w
ee
ks
RR
1.
12
(9
5%
C
I0
.8
0
to
1.
55
);a
RR
0.
95
(9
5%
C
I0
.6
3
to
1.
45
)b
88
%
St
ev
en
s
et
al
.
19
98
26
10
w
ee
ks
N
ot
re
po
rt
ed
N
A
N
ot
re
po
rt
ed
C
ou
ns
el
lin
g
N
ot
re
po
rt
ed
In
fo
rm
at
io
n
on
PA
an
d
he
al
th
,
an
d
lo
ca
l
fa
ci
lit
ie
s
8
m
on
th
s
RR
:1
.1
3
(9
5%
C
I0
.9
9
to
1.
30
);a
RR
1.
13
(9
5%
C
I0
.9
9
to
1.
30
)b
35
%
H
ar
ris
on
et
al
.
20
04
15
12
w
ee
ks
2
1
ho
ur
G
ro
up
an
d/
or
in
di
vi
du
al
C
ou
ns
el
lin
g;
su
bs
id
is
ed
ex
er
ci
se
se
ss
io
ns
N
ot
re
po
rt
ed
W
rit
te
n
in
fo
rm
at
io
n
on
ly
6
m
on
th
s,
9
m
on
th
s
an
d
12
m
on
th
s
RR
1.
27
(9
5%
C
I0
.8
4
to
1.
90
);a
RR
1.
23
(9
5%
C
I0
.8
0
to
1.
89
)b
84
%
So
re
ns
en
et
al
.
20
06
27
4
m
on
th
s
2
fo
r
fir
st
2
m
on
th
s,
1
fo
r
se
co
nd
2
m
on
th
s
1
ho
ur
G
ro
up
C
ou
ns
el
lin
g;
su
pe
rv
is
ed
ex
er
ci
se
se
ss
io
ns
Tr
an
st
he
or
et
ic
al
m
od
el
Lo
w
-in
te
ns
iv
e
in
te
rv
en
tio
n
(P
A
co
un
se
lli
ng
)
4
m
on
th
s
an
d
10
m
on
th
s
4
m
on
th
s:
48
m
in
ut
es
pe
r
w
ee
k
(9
5%
C
I3
1
to
12
8
m
in
ut
es
pe
r
w
ee
k)
;
10
m
on
th
s:
10
48
m
in
ut
es
pe
r
w
ee
k
(9
5%
C
I7
4
to
94
48
m
in
ut
es
pe
r
w
ee
k)
c
92
%
Is
aa
cs
et
al
.
20
07
18
10
w
ee
ks
2
45
m
in
ut
es
G
ro
up
an
d/
or
in
di
vi
du
al
Su
pe
rv
is
ed
ex
er
ci
se
se
ss
io
ns
N
ot
re
po
rt
ed
A
dv
ic
e
on
ly
(t
ai
lo
re
d
PA
ad
vi
ce
,
in
fo
rm
at
io
n
on
lo
ca
lf
ac
ili
tie
s)
6
m
on
th
s
an
d
1
ye
ar
M
ea
n
di
ff
er
en
ce
45
.0
0
(9
5%
C
I–
31
.4
2
to
12
1.
42
);d
RR
1.
19
(9
5%
C
I0
.9
1
to
1.
55
);a
RR
1.
05
(9
5%
C
I0
.7
8
to
1.
42
)b
10
0%
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
46
St
u
d
y
Sc
h
em
e
d
u
ra
ti
o
n
N
u
m
b
er
o
f
se
ss
io
n
s
p
er
w
ee
k
D
u
ra
ti
o
n
o
f
ex
er
ci
se
se
ss
io
n
s
G
ro
u
p
o
r
in
d
iv
id
u
al
C
o
m
p
o
n
en
ts
Th
eo
re
ti
ca
l
b
as
is
C
o
n
tr
o
lc
o
n
d
it
io
n
Fo
llo
w
-u
p
Ef
fe
ct
iv
en
es
s
A
d
h
er
en
ce
G
us
ie
t
al
.
20
08
28
6
m
on
th
s
3
50
m
in
ut
es
G
ro
up
Su
pe
rv
is
ed
ex
er
ci
se
se
ss
io
ns
N
ot
re
po
rt
ed
Be
st
ca
re
in
ge
ne
ra
l
pr
ac
tic
e
(in
co
rp
or
at
in
g
br
ie
f
ad
vi
ce
)
6
m
on
th
s
N
ot
re
po
rt
ed
86
%
D
ud
a
et
al
.
20
14
17
12
w
ee
ks
N
ot
re
po
rt
ed
N
A
G
ro
up
an
d/
or
in
di
vi
du
al
C
ou
ns
el
lin
g;
se
lf-
m
an
ag
em
en
t
bo
ok
le
t
SD
T
St
an
da
rd
ER
S
pr
ov
is
io
n
3
m
on
th
s
an
d
6
m
on
th
s
N
ot
re
po
rt
ed
55
.6
%
M
u
rp
h
y
et
al
.
20
12
23
16
w
ee
ks
1
N
o
t
re
p
o
rt
ed
G
ro
u
p
an
d
/o
r
in
d
iv
id
u
al
C
o
u
n
se
lli
n
g
;
su
b
si
d
is
ed
ex
er
ci
se
cl
as
se
s
M
o
ti
va
ti
o
n
al
in
te
rv
ie
w
in
g
N
o
rm
al
ca
re
an
d
b
ri
ef
w
ri
tt
en
in
fo
rm
at
io
n
12
m
o
n
th
s
M
ea
n
d
if
fe
re
n
ce
:
58
.1
1
[1
6.
38
,9
9.
84
];
d
R
R
:1
.1
0
[1
.0
1,
1.
20
];
a
R
R
:1
.0
5
[0
.9
5,
1.
17
]b
43
.8
%
H
EA
,
H
ea
lth
Ed
uc
at
io
n
A
ut
oh
rit
y;
N
A
,
no
t
ap
pl
ic
ab
le
;
PA
,
ph
ys
ic
al
ac
tiv
ity
.
a
N
um
be
r
ac
hi
ev
in
g
90
–
15
0
m
in
ut
es
PA
/w
ee
k
(d
en
om
in
at
or
s
as
re
po
rt
ed
)
RR
s
an
d
95
%
C
Is
.
b
N
um
be
r
ac
hi
ev
in
g
90
–
15
0
m
in
ut
es
PA
/w
ee
k
(IT
T
an
al
ys
is
),
RR
s
an
d
95
%
C
Is
.
c
In
te
rv
en
tio
n
vs
.
co
nt
ro
l.
Po
si
tiv
e
va
lu
e
in
th
e
co
m
pa
ris
on
in
di
ca
te
s
an
im
pr
ov
em
en
t
in
th
e
ER
S
gr
ou
p
co
m
pa
re
d
w
ith
th
e
co
nt
ro
li
nt
er
ve
nt
io
n.
d
M
ea
n
di
ff
er
en
ce
(t
ot
al
m
in
ut
es
of
m
od
er
at
e
to
vi
go
ro
us
ph
ys
ic
al
ac
tiv
ity
),
95
%
C
Is
.
N
ew
ev
id
en
ce
is
hi
gh
lig
ht
ed
in
bo
ld
in
th
e
ta
bl
e.
DOI: 10.3310/hta19600 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 60
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Campbell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
Summary
l An exhaustive search of electronic databases, hand-searching journals, bibliographic searches and
citation searching, identified 9871 titles published since 2009. Eighty full-text articles were retrieved.
l This review is an update of an earlier systematic review by Pavey et al.11 This update also included the
study by Murphy et al.23 This review has incorporated additional data supplied by the study authors.
Further additional data have also been incorporated exploring issues of uptake and adherence.
l One additional RCT,23 by Murphy et al., was identified since publication of the Pavey et al.11 HTA. The
study author supplied additional data, allowing an update of the meta-analyses exploring the impact of
referral to and ERS minutes of physical activity as measured using a 7-day physical activity recall, and
the number of participants achieving 90–150 minutes of physical activity per week.
l When the effectiveness of an ERS is compared with usual-care group that is receiving advice only,
the RR of achieving 90–150 minutes of physical activity per week at 6–12 months’ follow-up is 1.12
(95% CI 1.04 to 1.20). This is lower than the RR reported earlier by Pavey et al.11 (RR 1.16, 95% CI
1.03 to 1.30).
l The meta-analysis of minutes of total physical activity/per week at 6–12 months’ follow-up also showed
an increase of 55.10 minutes (95% CI 18.47 to 91.73 minutes) for those in the ERS groups compared
with those receiving advice only in the control groups.
TABLE 20 Detailed description of ERS interventions reported across included studies
Study Description
Taylor et al. 199812/200525 Exercise prescription and 10-week programme of reduced-price sessions at a leisure centre
(group and/or individual)
Stevens et al. 199826 Two consultations centred around becoming more active with a focus on what participants
already did, options for becoming more active and keeping a physical activity diary (no
formal exercise sessions) (group and/or individual)
Harrison et al. 200415 Consultation at a leisure centre followed by subsidised 12-week borough-wide leisure pass;
participants were encouraged to attend at least two centre-based sessions a week (group
and/or individual)
Sorensen et al. 200627 Health profiles (lifestyle and health questions) and motivational counselling (based on the
transtheoretical model of behaviour change), followed by 4-month group-based training
involving aerobic conditioning (e.g. Nordic walking and aerobics), light strength
conditioning, stretching and games, with additional health profiles and motivational
counselling after 2 and 7 months (group)
Isaacs et al. 200718 Instructor-led exercise classes in a leisure-centre setting (types of class available were
aerobics, body conditioning, aqua-aerobics, gymnasium and an optional swimming class)
and instructor-led walks (graded 1–5 on difficulty, participants could choose) (group and/or
individual)
Gusi et al. 200828 Supervised walks that consisted of walking alternating with specific exercises (joint mobility,
brisk walking, strengthening, stretching and brisk walking with footsteps and hand claps)
(group)
Duda et al. 201417 Consultations based on SDT: initial 1-hour one-to-one person-centred interview, including
optional fitness appraisal and exercise promotion booklet, then 15–20 minute face-to-face
or telephone consultation at 1 month, a brief 5-minute telephone call at 2 months, followed
by a 20- to 30-minute face-to-face or telephone consultation at 3 months, including a
self-management booklet centred on maintaining physical activity (group and/or individual)
Murphy et al. 201223 Motivational interviewing – initial consultation with an exercise professional
(including introduction to leisure-centre facilities and goal-setting), 4-week
telephone contact, 16-week consultation and then an 8-month telephone contact
and 12-month review, plus discounted access to one-to-one and/or group exercise
classes (group and/or individual)
New evidence is highlighted in bold in the table.
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l Murphy et al.23 is the largest RCT published to date and was considered to be at low risk of bias. It was
undertaken in Wales, and its findings are highly relevant to the UK context.
l Murphy et al.23 reported that referral and participation in ERS increased physical activity significantly for
those referred for CHD risk factors (OR 1.29, 95% CI 1.04 to 1.60). However, among those referred
for mental health reasons, either solely or in combination with CHD, there was no difference in physical
activity between the ERS and normal-care participants at the 12-month follow-up. The effect of being
in the ERS group on all referrals was an increase in levels of physical activity at 12 months, but this
finding was of borderline statistical significance (OR 1.19, 95% CI 0.99 to 1.43).
l No additional new evidence was available for the impact of ERSs on physical fitness, patient
satisfaction, clinical factors or adverse effects.
l The only significant improvements that have been measured for people referred to ERSs are in
self-reported measures of physical activity. These types of measures may be vulnerable to self-report
bias, particularly in the absence of blinding at outcome assessment. Only two studies attempted to
blind those collecting outcome data to the participants’ allocated groups. There was no evidence that
the interventions lead to positive changes in body fat, BMI or blood pressure.
l Subgroup analyses offer some insights into which groups of people are most like to take up and
adhere to ERS. The evidence is not consistent across the trials. Those who adhere to the scheme are
most likely to increase levels of physical activity. Those with higher levels of physical activity at baseline
are also more likely to increase levels of physical activity. There is also some evidence that those
referred for CHD risk factors are more likely to increase their levels of physical activity.
l Despite exploring the differences between the ERSs, it was not possible to identify particular features of
the interventions that promoted changes in levels of physical activity.
l The cut-off point for ‘sedentary’ seems quite high and in most studies related to not meeting physical
activity guidelines, which may be problematic as it would capture those with a broad range of activity
levels. Around one-half of the studies did not specify that it was necessary to be sedentary for referral
to the scheme, which again has implications for the interpretation of the findings.
l Interventions with a theoretical basis did not provide much explicit detail on how the theory drove
the intervention.
Barriers and facilitators of referral, uptake and adherence to
exercise referral schemes
Quantitative results of randomised controlled trial and observational studies
Quantitative analyses of the predictors of uptake and adherence to ERSs have been explored by Pavey
et al.11 It is beyond the scope of this short report to update this element of the review. However, as new
data have become available we have added these to the data from the existing Pavey et al.11 review.
Pavey et al.11 identified five RCTs and 14 observational studies for inclusion in their review. One additional
trial23 and two observational studies34,36 were identified for inclusion in this update, although our search for
new observational data was not exhaustive. See Table 21 for a summary of uptake and adherence to ERSs
across studies.
Sample sizes ranged across studies from 30 to 6610 participants in the observational studies and from
97 to 2068 in the RCTs. Mean age ranged from 44.9 to 51.9 years across the observational studies and
from 53.0 to 59.1 years for the RCTs. Uptake and adherence were described differently in the included
studies. Uptake was defined in one of two ways: attendance at the initial consultation with the ‘exercise
professional’ or attendance at least one exercise session.
Most studies provided a definition of adherence – completion of a set number of exercise sessions, either
numerically (e.g. completed 20 sessions) or a percentage (e.g. > 80% attendance). For four studies,37–40
attendance at a post-ERS consultation was also required to meet the definition of adherence.
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TABLE 21 Summary of uptake and adherence to ERS across studies
Study
Uptake Adherence
% (n/N)
% (n/N) of patients
who took up ERSs
% (n/N) of patients who
were referred to ERSs
RCTs
Taylor et al.,12 UK 88 (85/97) 28 (24/85) 25 (24/97)
Stevens et al.,26 UK 35 (126/363) Not reported Not reported
Harrison et al.,41 UK 84 (232/275) Not reported Not reported
Isaacs et al.,18 UK 92 (293/317) 45 (133/293) 42 (133/317)
Sorensen et al.,27 UK 100 (28/28) Not reported Not reported
Murphy et al.,23 UK 85 (919/1080) 51 (473/919) Completed 16 weeks:
43.8 (473/1080)
Partial attendance 41.3
(446/1080)
Observational studies
Damush et al.,42 USA 28 (113/404) Not reported Not reported
Dinan et al.,43 UK 89 (216/242) 82 (178/216) 74 (178/242)
aDugdill et al.,4 UK B: 68 (1825/2696) A: 34 (336/958);
B: 46 (849/1829)
B: 32 (849/2698)
Edmunds et al.,44 UK Not reported 51 (25/49) Not reported
Harrison et al.,41 UK 79 (5225/6610) Not reported Not reported
Jackson et al.,45 UK Not reported 70 (466/686) Not reported
Jones et al.,46 UK 78 (119/152) 65 (77/119) 51 (77/152)
Lord and Green,47 UK 60 (252/419) 31 (77/252) 18 (77/419)
Martin and Woolf-May,48 UK Not reported 12 (60/490) Not reported
Morton et al.,36 UK Not reported 40 (12/30) Not reported
Roessler and Ibsen,37
Denmark
Not reported 70 (811/1156) Not reported
Sowden et al.,38 UK 58 (3565/6101) 39 (1404/3565) 23 (1404/6101)
James et al.,49 UK Not reported 57 (750/1315) Not reported
bGidlow et al.,39
Crone et al.,40
James et al.,49 UK
66 (1930/2908) 48 (931/1930) 32 (931/2908)
Tobi et al., UK24 Not reported 58 at 13 weeks
(407/701)
Not reported
45 at 20–26 weeks
(315/701)
Hanson et al.,50 UK 81(1811/2233) 53.5 at 12 weeks
(968/1811)
43.3 (968/2233)
at 12 weeks
42.9 (777/1811)
at 24 weeks
34.8 (777/2233)
at 24 weeks
a Two schemes evaluated: schemes A and B.
b Average of the three publications.
New evidence is highlighted in bold in the table.
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The uptake of ERSs across the RCTs ranged from 35% to 100%. Murphy et al.23 had an uptake of 85%,
which was slightly above the pooled result (80%, 95% CI 61% to 98%) reported in the Pavey et al.11
review. Adherence to the scheme throughout compares favourably with the pooled rate of 37% (95% CI
20% to 54%) across schemes assessed by trials in the review.
Levels of uptake to ERSs ranged from 28% to 81% in the observational studies and adherence ranged
from 12% to 70%. Two additional studies36,48 reported adherence levels of 58% and 54%.
Demographic factors
Four studies23,38,47,49 found that women were more likely to take up ERSs than men, but two studies41,44
found no association between sex and uptake. The data for adherence, however, are less consistent, with
one study49 reporting that men are more likely to adhere to ERSs than women and another that women
are more likely to adhere to ERSs.51 Increasing age was a factor that strongly predicted for both uptake of
ERSs and adherence to the scheme in six studies.6,23,24,38,49,51 Three studies found no such association.18,42,47
Three studies23,39,49 found that those most deprived were less likely to take up ERSs and two studies23,49
found that deprivation was a predictor for not adhering to ERSs. Two studies23,49 found no such association
with take up. Car ownership23 was also a predictor of both uptake and adherence to ERSs. Living in a rural
location was also found to be associated with a lower likelihood of uptake.39 Two studies24,42 found no
association between ethnicity and uptake, and one found no association with adherence.24 Those most
active at baseline were also most likely to take up and to adhere to ERSs.51
Tables 22–24 describe the factors that have been associated with uptake and adherence in the
included studies.
Medical diagnosis
The evidence for the role of medical conditions at baseline in influencing both uptake and adherence is
not consistent across the studies.
Harrison et al.41 found that those with mental health problems were more likely to take up ERSs than
those with no specified referral reason (OR 1.70, 95% CI 1.24 to 2.39). Gidlow et al.39 found that those
with mental health problems were less likely to take up ERSs than those referred with cardiovascular
disease (OR 0.33, 95% CI 0.27 to 0.57). Gidlow et al.39 and Moore et al.52 both found that those with
mental health conditions were less likely to adhere than those referred for other reasons (Gidlow et al.39
22% vs. 34%; Moore et al.52 OR 0.57, 95% CI 0.43 to 0.75).
Harrison et al.41 found that the response to referral for respiratory problems was associated with
deprivation, with those most deprived less likely to take up ERSs than those least deprived (OR 1.45,
95% CI 1.06 to 1.99).
Participants referred because of overweight or obesity were found to be less likely to take up the
intervention39 (OR 0.63, 95% CI 0.50 to 0.81; p< 0.01) or to adhere50 to the intervention than those
without these problems. However, this factor was not significant in two other studies14,23
Those referred with musculoskeletal or orthopaedic problems were also less likely to take up ERSs39
(OR 0.75, 95% CI 0.58 to 0.99). Tobi et al.24 also found that they were less likely than participants with
metabolic conditions to adhere to ERSs (OR 0.25, 95% CI 0.07 to 0.94).
Participants referred with CHD risk factors were also found to have lower odds of adhering than those
with metabolic conditions24 (OR 0.18, 95% CI 0.05 to 0.70).
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Sowden et al.38 reported that patients with diabetes mellitus were less likely to adhere to an ERS (OR 0.76,
95% CI 0.63 to 0.93) than those with cardiovascular disease (CVD) (OR 1.22, 95% CI 1.03 to 1.45) when
compared with those without either condition.
Psychosocial
Pavey et al.11 reports the results of three studies36,44,46 that assess the psychosocial predictors of adherence.
Morton et al.36 found participant self-determination to positively predict ERS adherence, whereas Edmunds
et al.44 found no such association. An expectation for change in personal development was also found
to be positively predictive of ERS adherence.
Qualitative evaluation of the discussion sections of included studies
In order to explore a further source of data to improve understanding of the factors that will influence the
uptake of and adherence to ERSs, we undertook a qualitative analysis of the discussion and conclusion
sections of the included studies. Often authors will report their perceived reasons for success and failure of
interventions. These may not be reported in the measurable outcomes described within the results sections
of published papers and these views can give valuable additional insights that are particularly relevant to
the studies included in the review.
As a result of this analysis we created a logic model to summarise and describe the complexity of factors
that might impact on referral to ERSs, uptake, adherence and sustained change in levels of physical activity.
Factors that impact on the patterns of referral to exercise referral schemes
Crucial to the success of exercise referral programmes is ensuring that all those who might benefit are
referred. This was identified in a number of the studies as an area that impacted on intervention
effectiveness. Where researchers were involved in supporting the referral process, referral rates improved.
Low referral rates were reported in studies in which only one GP was involved in making referrals and in
pragmatic ‘real-world’ studies.28,33,34
Factors that were perceived to reduce health professionals’ referral to ERSs were lack of enthusiasm for
the project, poor knowledge of the scheme and poor interpersonal skills on behalf of the health
professional.12 Workload and competing demands and the extra time needed to make the referral were
also considered barriers to referral.26 There was also a view that certain characteristics of individuals might
TABLE 24 Summary of analysis of psychosocial factors that predict adherence
Psychosocial factors
Edmunds
et al.44
Jones
et al.46
Morton
et al.36
Number of studies
on this factor + –
No significant
association
Stage of change 0 1 1
Self-efficacy 0 1 1
Expectations of change
(health and fitness)
0 1 1
Expectations of change
(personal development)
+ 1 1
Psychological well-being 0 1 1
Need satisfaction 0 1 1
Perceived autonomy 0 1 1
Support 0 1 1
Self-determination + 1 1
+, positive association; –, negative association.
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influence the likelihood of referral. Being younger appeared, in one study, to reduce the likelihood of
being referred.18
An invitation that was perceived by those referred to be judgemental in its tone was a barrier to the
uptake of an ERS. Other aspects of the invitation that were more likely to lead to a positive response
included issuing invitations with a specific appointment time. Where invitations required participants to
make the appointment, there was poorer response to the referral.26
An area where there is uncertainty about potential factors that might influence referral and response to
referral is in the use of cold calling by health professionals as an alternative to the GP referring following a
consultation.12 There may also be a potential role for peers in the process of referral and uptake that is as
yet unexplored.28
Factors that influence uptake of exercise referral schemes
A number of characteristics of the intervention were described as being factors that might shape the
uptake of ERSs and adherence to the programme. The attractiveness and appeal of the intervention was
felt to be important, particularly in targeting these to the individuals most likely to benefit from the
intervention.18 Using an existing scheme was also felt to be advantageous.12 The incorporation of
motivational counselling, ongoing professional support and the quality of that counselling and support
were considered important factors. Another element of motivational interviewing related to the fidelity of
the intervention, with poor delivery compromising the effectiveness of the intervention.52 Interventions that
had tailored motivational strategies were seen as more likely to be taken up and adhered to than ones in
which there was a lack of choice. Schemes where support was given in a non-judgemental way were
considered important.52 The speed of referral was considered important, with congestion in the system a
barrier to uptake.12
There were aspects of ERS design where further research was recommended to establish its value; this
included the use of telephone calls to prompt attendance, follow-up sessions outside the scheme and the
addition of motivational counselling.14,21,33
A further barrier to uptake in trials of ERSs was that some participants did not want to be randomised.27
Factors influencing adherence and sustained change in physical activity levels
A number of factors, relating particularly to the environment, were considered important in maintaining
adherence to the programme and in maintaining levels of physical activity. These included perception of
the environment and, linked to this, the presence of parks and green spaces in the urban environment.18
An environment that is not, or is not perceived to be, conducive to changing levels of physical activity is a
barrier to sustained behaviour change. Programmes that included strategies to make gradual small
changes and move to levels of moderate activity, rather than interventions that promote more intense
levels of physical activity, were felt to have greater appeal and to be more likely to promote adherence
and sustained change.26
A range of characteristics of participants were also reported to make a difference to their response to
ERSs. Individuals who smoked were less likely to adhere to ERSs.12 The evidence for people with obesity
was more varied, with one study finding that those with obesity were more likely to take up the
intervention and adhere to it than non-obese participants12 and another finding the opposite.18 More
research might identify what features of the intervention made it attractive or less attractive to people with
obesity. Participants with greater pre-existing levels of physical activity were more likely to adhere to the
intervention.14,23 One paper raised the suggestion that those volunteering to participate may have already
been motivated to become (more) active.27 Along with reports that there were fewer referrals from more
deprived wards,18 this also raises the possibility that, as an intervention, ERSs may serve to increase
inequalities in health.
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Additional questions
A number of areas for further investigations were identified in the included studies. These included gaining
an understanding of the needs of particular groups; exploring why people withdraw from ERSs; and the
potential value of additional home support.17,21,23
The value of advice
Several studies explored the reasons why the intervention was not effective, when compared with
advice-only groups (usual care).17,21,34 One reason was that physical activity levels also increased in the
control groups that were receiving advice about the benefits of physical activity but were not referred to
an ERS. The reasons why advice works in the context of these trials, where individuals are deprived of the
intervention, warrants further exploration.
Qualitative sibling studies
We searched for qualitative studies that were undertaken as part of a mixed-methods evaluation of an ERS
included in this review.
One study23,25,26,32 undertook a mixed-method process evaluation, using structured observation, implementer
interviews and routine data to assess the extent to which the ERS was implemented as intended.
Semistructured patient interviews explored processes of change and the emergence of social patterning in
responses to the scheme.52
The features of the intervention were as follows: motivational interviewing – initial consultation with an
exercise professional (including introduction to leisure-centre facilities and goal-setting), 4-week telephone
contact, 16-week consultation and then an 8-month telephone contact and 12-month review, plus
discounted access to one-to-one and/or group exercise classes (group and/or individual).
The intervention recruited participants who were sedentary and who had at least one CHD risk factor or
suffered a mental health problem (mild anxiety, depression or stress).
The findings of the semistructured patient interviews are summarised.
Qualitative study component: patient experiences of the exercise
referral schemes
Entering the scheme: routes into exercise referral schemes and motivations
for attendance
Some patients described entering the ERS because their health professional had advised them to. However,
others described initiating referral themselves through asking their doctor to refer them, having made an
independent decision to become more active. In some centres, a majority of patients were referral seekers,
with some commenting that health professionals had been unaware of the scheme until made aware of it
by patients. Those who actively sought referral often had been previously active, but in many cases this
had been interrupted. Joining the ERS became a way of overcoming barriers to becoming active
once again.
Patients cited various motivations for attendance, including improved health outcomes such as reduced
blood pressure and weight loss. Both referral seekers and those advised to attend commonly also linked
behaviour change to personal values such as having a proactive role in treating and preventing illness.
Older patients emphasised maintenance of autonomy and ability to perform everyday activities as principal
motivators for attendance. For younger patients, however, primary motivations centred around maintaining
occupational functioning or returning to work, with many having attended because of injuries or illness
which prevented, or threatened to prevent, them from working.
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Experiences of exercise referral schemes
Those who attended the ERS for several weeks were beginning to perceive progress towards their goals.
Some mental health patients highlighted valued improvements in mood and increased social contact.
Others highlighted medical improvements, such as reduced breathlessness and blood pressure, increased
mobility or reduced pain. Lack of weight loss was a disappointment for several participants.
The expertise of the professionals and the support they offered was clearly an aspect of the interventions
that was valued, particularly in helping participants as they became familiar with using exercise equipment
and in knowing the extent to which they should exert themselves. The professional’s role in monitoring
progress and promoting further progression was also valued.
The lack of variety in the forms of exercise enabling progression was a negative element of the intervention
for some who were at the later stages of the programme. The limited number of centres where the scheme
was offered was potentially a barrier to participation, particularly if this meant that participation was
dependent on access to a car. Access was also more problematic for those who were working and were
more constrained by time.
Peer support and the value of shared experiences with other patients was a positive element of the
intervention, meaning that individuals felt that they would be viewed with empathy. Mixing with others
who were at later stages in the programme provided positive role models. This made the exercise
environment less intimidating and more supportive, which encouraged participants.
Leaving exercise referral scheme: the transition to independent activity
Some patients identified clear plans for how they would maintain increases in physical activity, sometimes
having identified exit route classes they planned to enter or focusing upon a desire to return to former
hobbies. Such patients were most commonly those with a prior history of activity, some of whom had
entered ERSs as a means of overcoming the refusal of gyms to accept them as members.
Others, perhaps more dependent on the programme to provide ideas for long-term maintenance or
activity, were unsure how they might maintain change. In some cases, formation of action plans appeared
to have been hampered by a lack of information about available options after the programme. Some
expressed concerns that, without a commitment to an agreed time and place, other aspects of daily life
would crowd out time for physical activity, with the ERSs providing justification for taking time out from
other commitments, but with this time becoming harder to protect after programme completion.
There were some differences in views between those at the early stages of the programme and those
nearing the end of the programme. For those at the early stage, they expressed concerns regarding their
ability to maintain increases without ongoing motivational and informational support from the professional.
For those near the end of the programme there were perceived challenges including the loss of social
support they gained while participating in the programme. The support element of having others to exercise
with was an important factor in maintaining levels of physical activity. For some, there were concerns about
moving into mainstream exercise settings as well as concerns about the cost of remaining active once the
programme discount was withdrawn.
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Summary
l Figure 15 is a logic model, seeking to represent the many factors that can impact the pathway from
sedentary levels of physical activity, to successful uptake and adherence to an ERS and to maintained
healthy levels of physical activity.
l Exercise referral schemes are ‘complex interventions’; therefore, what works in one setting may not
mean the intervention will necessarily work in another. It is, therefore, important to understand what
works, for whom and in what circumstances.
l When considering uptake and adherence, issues relating to who is referred and also to maintenance of
physical activity at the end of the intervention also need to be considered.
l A range of factors can influence who is referred to an ERS, including the support for referral, buy-in by
GPs and preconceived perceptions about patients by health professionals.
l A range of characteristics can shape how participants respond to referral. These include age, pre-existing
levels of physical activity and obesity. The nature of the invitation to an ERS can also shape response
from potential participants.
l Exercise referral schemes vary in many ways, including professional running schemes, group-based or
individual sessions and the incorporation of motivational counselling. They will also vary in duration of
contact and length of time in scheme. There is uncertainty over which elements of these schemes may
have benefits for which groups. There is some suggestion that group-based work can be beneficial in
promoting peer support. This in turn can promote sustainable change. It can make some individuals,
particularly men and older people and overweight individuals, feel more uncomfortable in group settings.
l Perceptions of the environment and the presence of green space supports sustained change.
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Chapter 4 Assessment of cost-effectiveness
Background to independent economic assessment
In 2011, Anokye et al.21 published the results of a cost-effectiveness model of ERSs based on data from a
systematic review of the effectiveness of ERSs by Pavey et al.11 They concluded that ERSs are associated
with a modest increase in lifetime costs and benefits and that the cost-effectiveness of ERSs is highly
sensitive to small changes in the effectiveness and cost of ERSs and is subject to some significant
uncertainty, mainly as a result of limitations in the clinical effectiveness evidence base.
This model was later amended to inform the NICE guidance on brief advice in primary care to promote
physical activity (PH44).53 This later model differed from that used by Pavey et al.11 in terms of both the
model structure and its data inputs (see Chapter 4, Comparison of the Anokye adapted to exercise referral
scheme model and the Pavey exercise referral scheme model for a comparison of these two models).
The scope for the economic analysis of ERSs for this brief report was to update the Anokye et al. brief
advice model with evidence from an updated systematic review on the effectiveness of ERSs and to update
the costs.53
The economic analysis has, therefore, focused on updating only three groups of parameters and all other
parameter values have remained unchanged. First, estimates of the relative clinical effectiveness of ERSs
versus no ERSs have been updated using the results from the updated systematic review given that the
review identified new evidence (see Chapter 3, Results). Second, costs were inflated to 2013 values using
Personal Social Services (PSS) Research Unit inflation indices.54 Third, the starting age has been set at
50 years, which is the mean age from the studies from which the effectiveness data have been taken.
No other model parameter values were updated and the model structure remains unchanged.
There are several benefits to using an existing cost-effectiveness model to assess the cost-effectiveness of
ERSs. Firstly, it builds on the existing evidence base already incorporated within the model, allowing
resources to be focused on identifying and incorporating any new effectiveness evidence. Secondly, the
repeated use of the same model across multiple NICE Public Health Appraisals is likely to increase internal
consistency within the NICE process. Conversely, the lack of a de novo approach does limit our ability to
explore alternative model structures and evidence sources. In this case, the use of an existing model was
determined to be the best option given the resources available, and the model to be used was specified a
priori in our protocol.
Methods
Population, intervention and comparator
The population, intervention and comparator are the same as those defined in Chapter 4, Comparison of
the Anokye adapted to exercise referral scheme model and the Pavey exercise referral scheme model.
Horizon and perspective
The analysis was conducted for a hypothetical cohort of 100,000 patients with a mean age of 50 years
receiving either exercise referral or usual care. A lifetime horizon was adopted in order to capture the
potential long-term benefits and cost savings associated with physical activity. Mean life expectancy was
based on UK interim life tables55 and the analysis did not consider males and females separately. The
economic perspective of the model is the NHS and PSS in the UK. Costs and health benefits were
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discounted at an annual rate of 1.5% as recommended by the Methods for the Development of NICE
Public Health Guidance.56
Model structure
The model structure is described in full elsewhere but we provide a brief description here.53 The model has
a Markov structure and considers a cohort of individuals aged 50 years who present in a physically inactive
state and are given a referral to a service designed to increase physical activity that includes a physical
activity or exercise programme compared with a control group with no referral to an exercise service. The
age of the population was selected to reflect the populations enrolled in the studies providing evidence on
the effectiveness of ERS.11,23 The model estimates the likelihood of becoming physically active and the
consequent risk reduction this has on CHD, stroke and type 2 diabetes mellitus.
In the first year of the model individuals enter either an ‘inactive, healthy state’ or an ‘active, healthy’ state;
this is considered a ‘run-in’ period where individuals reach a stable level of activity. From year 2 onwards,
a proportion of individuals transit from the initial state into one of the following states: event free, CHD,
stroke and type 2 diabetes mellitus. Stroke and CHD are then subdivided into non-fatal and fatal. Patients
can also die from other causes. Figure 16 shows the model structure.
Model parameters
Effectiveness of exercise referral schemes versus usual care
The evidence for the effectiveness of ERSs versus usual care is based on the results of the systematic review
described in Chapter 3 of this report. The review identified one new study by Murphy et al.23 This study
conducted a large RCT, with 2160 participants randomised to receive ERS or usual care. A full description
of the study can be found in Chapter 3 of this report. This study was combined in a meta-analysis with
the studies identified by Pavey et al.11 The RR of the number of individuals becoming active versus being
inactive owing to ERSs was 1.12 (95% CI 1.04 to 1.20). This RR was calculated using the number of
Fatal
Healthy
individuals
CHD
Stroke
Type 2
diabetes
mellitus
Fatal
Non-fatal
Non-fatal
All-cause
mortality
Non-fatal
FIGURE 16 Model structure from year 2 onwards.
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participants with study data at 12 months. A sensitivity analysis was also conducted using the RR estimated
when taking an ITT approach (RR 1.08, 95% CI 1.00 to 1.17).
The effect of physical activity on disease outcomes
Evidence of the effect of physical activity on the development of CHD, stroke and type 2 diabetes mellitus
was derived from a reference search of papers included in five national and international guideline reports
that set out the science-based guidance on physical activity, fitness, and health for the UK, USA and
Canada (see appendix 6 of Anokye et al.).53
The RR estimates for developing CHD (non-fatal and fatal), stroke (non-fatal and fatal) and diabetes
mellitus were selected from Hu et al.,57–59 respectively. These RR estimates were based on cohort follow-up
periods of 19 years for CHD and stroke and 12 years for diabetes mellitus. The model applies these RR
estimates for the initial 10-year period only on the assumption that it would be unrealistic for them to be
applied after the follow-up period (Table 25).
Physical activity habits can be quite changeable. The impact of changing habits is incorporated in the cohort
RR estimates for the disease conditions. The studies used followed up the same people (who were either
active or inactive at baseline) for a number of years, during which time some of the inactive people might
have become active or vice versa, diluting the observed relationships between activity and outcomes.60–62
Hence, the protective effect of activity is assumed to last for the period in which these people were
followed, that is 10 years.
The physical activity levels and study population used to measure the effect of activity on disease outcomes
were similar to those of the effectiveness estimate.
Baseline risk of developing the disease conditions
The baseline risks for developing CHD and stroke were based on age-specific UK annual incidence rates
used in a NICE technology appraisal of statins63 and the model developed as part of the update of the
NICE guideline on hypertension.64,65 In these models, data were obtained from the Bromley Coronary Heart
Disease Register and the Oxfordshire Community Stroke project. The baseline risk for diabetes mellitus was
taken from age-specific UK incidence rates for type 1 and type 2 diabetes mellitus from 1996 to 2005
estimated in Gonzalez et al.66 Table 26 shows the baseline risks for the disease conditions in the
general population.
The derivation of the probabilities for developing CHD, stroke and diabetes mellitus used in the model
involved a number of steps. First, the probability of developing these conditions among inactive people was
derived by adjusting the general population age-specific incidence rates using the attributable risk fraction.67
Second, the estimates were adjusted using RR estimates of the probability of developing the health states
among active individuals reported in Hu et al.57–59
The probability of a primary stroke or CHD event being fatal was based on incidence data from the
Bromley Coronary Heart Disease Register and the Oxfordshire Community Stroke project.63 This should be
acknowledged as a simplification of the model, as in reality these probabilities might depend on level of
physical activity. Lack of data, however, precluded accounting for such a possibility.
TABLE 25 Relative risk estimates for developing the disease conditions
Disease conditions RR (95% CI) Source
CHD 0.90 (0.83 to 0.99) Hu et al.56
Stroke 0.86 (0.79 to 0.93) Hu et al.57
Diabetes mellitus 0.67 (0.53 to 0.84) Hu et al.58
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Mortality risks
The probabilities for CVD- (CHD and stroke) and non-CVD-related mortality for healthy people were
derived from age-specific UK interim life tables prepared by the Government Actuary’s Department that
were adjusted by age-specific UK annual incidence of mortality prepared by the Office for National
Statistics (see Appendix 4). Although it is recognised that these estimates relate to the general population
and, hence, include people with CHD, stroke and diabetes mellitus, the percentages of those disease
groups are relatively small (< 8%) and, hence, we assume that these estimates are applicable to the
healthy population. RR estimates for CHD-, stroke- and non-CVD-related mortality among people with
CHD, stroke and diabetes mellitus were used to adjust the probabilities for the healthy people to derive
probabilities of CHD-, stroke- and non-CVD-related mortality (see Table 27). The RR estimates for diabetic
patients were based on a cohort of the Framingham Heart Study (aged 45–74 years) that was followed for
up to 25 years in the Preis et al. study.60 For stroke patients, data were obtained from Brønnum-Hansen
et al.61 who followed a Danish cohort of > 25-year-olds for 10 years after their first non-fatal stroke. As no
equivalent data were found for CHD patients the model assumes CHD risk is the same as stroke risk. The
relative risks for mortality applied in the model are summarised in Table 27.
Utility values
Health state utility values were taken from Ward et al.,68 who undertook a wide search for available
evidence on utility estimates associated with CVD and diabetes mellitus health states (Table 28).
To account for the fact that HRQoL in the general population falls with age, the disease-specific utilities
were weighted using age-specific utility scores for the general population. The age-specific utility
scores were estimated using data from the Health Survey for England62 (see Table 29).
TABLE 26 Baseline risks for CHD, stroke and diabetes mellitus per annum
Age (years) CHD Stroke Diabetes mellitus Source(s)
33–34 0.000035 0.00008 – Ward et al.,63,68 NICE69
(33–39) – – 0.00009 Gonzalez et al.66
35–44 0.000465 0.00023 – Ward et al.,63,68 NICE69
(40–49) – – 0.00028 Gonzalez et al.66
45–54 0.002095 0.00057 – Ward et al.,63,68 NICE69
(50–59) – – 0.000632 Gonzalez et al.66
55–64 0.00631 0.00291 – Ward et al.,63,68 NICE69
(60–69) – – 0.001005 Gonzalez et al.66
65–74 0.0097 0.0069 – Ward et al.,63,68 NICE69
(70–79) – – 0.001116 Gonzalez et al.66
75–81 0.0097 0.01434 – Ward et al.,63,68 NICE69
(80–81) – – 0.001116 Gonzalez et al.66
TABLE 27 Relative risks for mortality after primary events
Mortality outcome After non-fatal CHD After non-fatal stroke After diabetes
Non-CVD mortality 1.71 1.71 1.49
CVD mortality 3.89 3.89 2.61
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Process utility
It is acknowledged that individuals benefit psychologically from physical activity, resulting in a so-called
process utility, and it has been estimated that there is an average increase in utility values of 0.072.11 Using
a conservative approach, this utility gain is assumed to last for only the first year, as the evidence in a study
by Campbell et al.70 indicates that this is the period when individuals stayed active. Sensitivity analysis
considers the impact of this quality of life (QoL) gain by setting it to zero in the univariate sensitivity analysis.
Intervention costs
An estimate of the cost of ERS was taken from Pavey et al.11 and is based on a HTA by Isaacs et al.,18 which
conducted a detailed micro-level costing exercise for a leisure centre-based ERS. Pavey et al.11 updated this
cost to 2010 prices (£222) and we have inflated this to a 2011/12 cost of £229 using inflation indices from
the PSS Research Unit.54 The cost to the participants is not included in the ERS model.
Treatment costs
Table 30 shows the annual costs per person attributed to the health states in the model. These costs were
taken from a National Clinical Guidelines Centre report that provided an updated review of costs for
various health states.69
TABLE 29 Age-specific quality of life62
Age (years) Mean SD
33–44 0.90 0.184
45–54 0.86 0.229
55–64 0.82 0.264
65–74 0.78 0.266
>75 0.72 0.275
SD, standard deviation.
TABLE 28 Condition-specific utility values – Ward et al.68
Condition Utility
Healthy 1
CHD initial event 0.8
Post-CHD event 0.92
Stroke initial event 0.63
Post-stroke event 0.65
Diabetes mellitus 0.9
TABLE 30 Treatment costs related to conditions
Conditions Annual cost per person (2011/12 prices, £)
Healthy 0
CHD initial event 4198
CHD annual treatment 480
Stroke initial event 10,839
Stroke annual treatment 2380
Diabetes mellitus annual treatment 968
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Individuals incur a one-off initial event cost when entering a CHD or stroke disease state. Furthermore,
for all three disease states (CHD, stroke and diabetes mellitus) individuals incur an ongoing treatment
cost for each year they remain in that disease state.
Injuries and adverse events
No new data relating to injuries and adverse events were identified in the systematic review and, therefore,
adverse events are not included in this analysis.
Subgroup analysis
Subgroup analysis was carried out for individuals with a diagnosed condition known to benefit from
physical activity. The three conditions included in the Pavey et al. HTA11 were obesity, hypertension and
depression. Table 31 shows the probabilities of being active and inactive associated with these conditions
taken from Pavey et al. and the calculated RRs that were used in these subgroup analyses. For events for
which data were not available, that is diabetes mellitus for the hypertensive cohort, base case values have
been assumed.
For the depressive subgroup analysis, data from the Murphy et al. study23 were provided to us
(Professor Simon Murphy, personal communication) for which enabled us to estimate the RR of achieving
recommended levels of physical activity for ERSs in a subgroup of individuals with a mental health referral
(RR 1.02, 95% CI 0.83 to 1.24). As these data were more directly applicable to the population with
depression, we have applied this as the base case efficacy parameter in this subgroup analysis. For the
obese and hypertensive subgroups, for which subgroup-specific effectiveness data were available, we have
applied the meta-analysed effectiveness data from all studies included in the clinical effectiveness review,
which are not specific to patients with these conditions. The results for the depressive cohort are also
provided using these RRs for comparison. All other parameter values are the same as the base case analysis.
Univariate sensitivity analysis
Univariate sensitivity analyses were undertaken to examine the impact of changes to a number of
parameter values on the cost-effectiveness results (Table 32). Following completion of the report, further
additional analyses were requested by the NICE Public Health Appraisal Committee (PHAC). These
additional analyses are summarised in Appendices 6 and 7.
TABLE 31 Data applied in the subgroup analysis11
Risks of adverse health outcomes by comorbidity Relative risks Condition Calculated RRs
Obese
Probability of experiencing CHD when active 0.0259 CHD 0.6888
Probability of experiencing CHD when inactive 0.0376
Probability of experiencing stroke when active 0.0259 Stroke 0.6888
Probability of experiencing stroke when inactive 0.0376
Probability of experiencing type 2 diabetes mellitus when active 0.0756 Diabetes
mellitus
0.7667
Probability of experiencing type 2 diabetes mellitus when inactive 0.0986
Hypertensive
Probability of experiencing CHD when active 0.060 CHD 0.8108
Probability of experiencing CHD when inactive 0.074
Probability of experiencing stroke when active 0.060 Stroke 0.8108
Probability of experiencing stroke when inactive 0.074
Depressive
Probability of experiencing CHD when active 0.0336 Depressive 0.4195
Probability of experiencing CHD when inactive 0.0801
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Probabilistic analysis
Uncertainties around all parameters in the model (except baseline mortality) are addressed simultaneously
using probabilistic sensitivity analyses (PSAs). Baseline mortality data were excluded from the PSA because
mortality data come from census data and national databases where the uncertainty in the mean estimates
is expected to be small.
The choice of distributions and their respective alpha and beta calculations draws on Briggs et al.64 In cases
where there are no data on standard errors they were subjectively assigned at 10% of the mean value.
We have checked that the model results are stable and this information was used to determine the
number of runs (10,000).
Results
Deterministic results
Table 33 shows the cost-effectiveness results per individual person based on point estimates of parameter
values. The deterministic analysis indicates that ERSs are expected to produce a small health gain [0.003
quality-adjusted life-years (QALYs)] at an additional cost of £225 compared against usual care. This
resulted in an incremental cost-effectiveness ratio (ICER) of £76,059 per QALY gained.
TABLE 33 Deterministic results
Intervention Mean cost (£) Mean QALY Incremental cost (£) Incremental QALY ICER (£)
ERS 4572 18.136 225.4 0.003 76,059
Usual care 4346 18.133 – – –
TABLE 32 Overview of univariate sensitivity analysis
Purpose (impact of) Parameter Changes in parameter estimates
Changes in people who become
physically active (at 1 year) after
exposure to ERSs
Effectiveness
estimate (via RR)
1. Threshold analysis: at what levels does the ICER fall below
£20,000/£30,000
2. ITT analysis
Changes in persistence of
protective effects (adjusted for
decay rates) of physical activity
RR for developing
disease conditions
Base case= protective effects persists up to 10 years. Changes:
1. Protective effects persist over lifetime = applying the same RR
used for the first 10 years for the rest of the lifetime
2. Protective effects persist just for a year= apply RR to first year
(rather than 10 years) and the remaining years take RR= 1
Changes in discount rate Discount rate Change discount rate for costs and QALYs from 1.5% to 3.5%
Assuming no psychological QoL
gain from physical activity
Process utility Change process utility from 0.072 to 0.000
Process utility lasts longer Process utility Threshold analysis.
Risk of developing disease
conditions change
RR of developing
disease
RRs from Pavey et al.11
Lower intervention cost Intervention cost Threshold analysis
Change in QoL utility values QoL utility QoL utilities from Pavey et al.11
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
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Probabilistic results
Table 34 shows the PSA results per individual person. The PSA results are very similar to the deterministic
results, with an ICER of £76,276.
Figure 17 shows a cost-effectiveness plane of the probabilistic results. Although all of the PSA estimates
indicate a positive health gain and increase in costs, there is uncertainty in the magnitude of that cost and
QALY gain. However, as can be seen from the cost-effectiveness acceptability curve in Figure 18, the
probability that ERSs are cost-effective at a willingness-to-pay threshold of £30,000 per QALY gained is
only 0.004.
TABLE 34 Probabilistic sensitivity analysis results
Intervention Mean cost (£; 95% CI) Mean QALY (95% CI)
Incremental
cost (£)
Incremental
QALY ICER (£)
ERS 4570 (4568 to 4571) 18.1284 (18.006 to 18.161) 226 0.0030 76,276
Usual care 4344 (4342 to 4346) 18.1254 (18.093 to 18.158) – – –
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Univariate sensitivity analysis
Univariate sensitivity analyses were undertaken to examine the impact of assumptions about the
effectiveness of ERSs, the duration of the protective effect of physical activity and the discount rate on
the cost-effectiveness of ERSs compared with usual care. Table 35 lists the effect of these changes.
The model is very sensitive to increases of the RR of ERSs on physical activity uptake, with a small increase
from 1.12 to 1.31 leading to the ICER falling below £30,000 per QALY gained. Using an ITT approach to
estimate the efficacy of ERSs compared with usual care reduced the RR to 1.08 and substantially increased
the ICER to over £100,000 per QALY. Increasing the protective effect of physical activity over the duration
of an individual’s lifetime leads to an ICER that is around £33,000 per QALY gained. However, as
expected, excluding the process utility raises the ICER considerably, whereas assuming that this utility lasts
for 4 years reduces the ICER to around £28,000 per QALY gained. Using the Pavey et al.11 RRs of developing
physical activity-related diseases leads to an ICER of around £38,000. A 60% reduction in the cost of the
intervention is required before the ICER falls below £30,000. Using the Pavey et al.11 utilities results in an
ICER of around £62,000.
Results for the additional analyses requested by PHAC are summarised in Appendices 6 and 7.
Results of the subgroup analysis
Tables 36–39 show the results of the subgroup analysis. In all subgroups, the ICER is above £37,000.
TABLE 35 Results of the univariate sensitivity analysis
Parameter Baseline Sensitivity analysis
ICER (£)
(baseline £76,000)
RR of effectiveness of ERSs on physical
activity uptake
1.12 1.31 < 30,000
1.47 < 20,000
1.08 (ITT) 113,931
Length of protective effect of physical
activity
10 years 1 year 124,193
Lifetime 33,056
Discount rate 1.5% 3.5% 88,943
Process utility 0.072 0 188,834
Process utility threshold analysis: how
long does the effect need to last for the
ICER to fall below £30,000 per QALY?
First year only 4 years 27,893
RR of developing disease (active vs.
inactive)
CHD 0.9 0.52 37,676
Stroke 0.86 0.73
Diabetes mellitus 0.67 0.5
Intervention cost threshold analysis:
reduction required to achieve an ICER
< £30,000 per QALY
£229 60% reduction (£92) 29,746
Utility values for disease states changed
to those used by Pavey et al.11
CHD initial event 0.8 0.55 62,343
Ongoing CHD 0.92
Stroke initial event 0.63 0.52
Ongoing stroke 0.65 0.70
Diabetes mellitus 0.90
DOI: 10.3310/hta19600 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 60
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Campbell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
Comparison of the Anokye adapted to exercise referral scheme model and
the Pavey exercise referral scheme model
The aim of this short report was to adapt the Anokye et al.21 brief advice model into a model comparing
ERSs with usual care. The parameters we changed were replacing the RR of brief advice versus usual care
with the same RR of ERSs versus usual care used by Pavey et al.,11 changing the starting age from 33 years
to 50 years to reflect the Pavey et al. data and inflating all costs to 2011–12 values. The adapted model
appears to generate results that are less favourable to ERSs, even though the effectiveness estimate
applied in the updated model is slightly more favourable. We will attempt here to explain why the model
results differ in a manner not explained solely by the update of efficacy evidence. We do not have access
to the Pavey et al.11 model and so our explanation of these discrepancies is based on the Pavey et al.
health technology report.
Comparison of model structure
The aim of the Pavey et al.11 model is the same as the adapted model, that is, to assess the impact of
ERSs on CHD, stroke and diabetes mellitus through the beneficial effects of increased physical activity.
The intervention (and effectiveness of the intervention), comparator, perspective and time horizons are the
same in both models. The two main differences are:
(a) Pavey used a decision tree approach whereas the adapted model has a Markov structure
(b) the benefits of physical activity were assumed to be constant over lifetime in Pavey et al.,11 whereas in
the adapted model, the benefits of physical activity are limited to 10 years
(c) many of the input parameters differ as detailed in Comparison of input parameters.
TABLE 36 Obese cohort using base case RR for effectiveness of ERSs
Intervention Mean cost (£) Mean QALY Incremental cost (£) Incremental QALY ICER (£)
ERS 4764 18.063 221 0.005 45,905
Usual care 4543 18.058 – – –
TABLE 37 Hypertensive cohort using base case RR for effectiveness of ERSs
Intervention Mean cost (£) Mean QALY Incremental cost (£) Incremental QALY ICER (£)
ERS 4632 18.111 224 0.004 61,602
Usual care 4408 18.107 – – –
TABLE 38 Depressive cohort using Murphy et al. subgroup data for effectiveness of ERSs (Professor Simon Murphy,
personal communication)
Intervention Mean cost (£) Mean QALY Incremental cost (£) Incremental QALY ICER (£)
ERS 4695 18.035 228 0.001 227,948
Usual care 4467 18.034 – – –
TABLE 39 Depressive cohort using base case RR for effectiveness of ERSs
Intervention Mean cost (£) Mean QALY Incremental cost (£) Incremental QALY ICER (£)
ERS 4688 18.040 221 0.006 37,488
Usual care 4467 18.034 – – –
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Comparison of input parameters
Relative risks
In Pavey et al.,11 the RR for developing a disease for active versus inactive individuals was 0.52, 0.73 and
0.5 for CHD, stroke and diabetes mellitus, respectively. In the adapted model the RR was 0.9, 0.86 and
0.67, respectively. The effect of using Pavey et al.’s11 RRs is explored in our sensitivity analysis. Table 40
shows the parameters used and describes the sensitivity analysis conducted to explore their impact on
cost-effectiveness.
Quality-of-life utility values
Table 40 also shows the health state utility values in the two models. The values used by Pavey et al.11
are markedly lower than those in the updated model.
Costs
Pavey et al.11 report the discounted (3.5%) lifetime costs of CHD, stroke and diabetes mellitus used in their
model (shown in Table 41, inflated to 2011/12 prices). They also assume an average length of life-years
remaining of 18.41, 5.12 and 28.13 for CHD, stroke and diabetes mellitus respectively. In order to
compare the lifetime costs of Pavey et al.11 with the updated model we used the following method to
estimate lifetime costs in our model:
1. apply discounting to the estimate of life expectancy for each health condition to estimate the
discounted life-years gained in each health state
2. multiply the discounted life-years by the ongoing cost of the condition used in the updated model
3. add on the cost of the initial event for the condition (zero for diabetes mellitus) used in the
updated model.
Table 41 shows the discounted lifetime costs used in the Pavey et al.11 model and the estimates from the
updated model. The costs vary widely between the two models.
TABLE 40 Parameter inputs to the sensitivity analysis
Change in the RRs associated with active vs. inactive people developing a disease to those used by Pavey et al.11
RRs Current Pavey et al.
CHD 0.9 0.52
Stroke 0.86 0.73
Diabetes mellitus 0.67 0.50
Change in the QoL utility values for disease states to those used by Pavey et al.11
Health state utility values Current Pavey et al.
CHD initial event 0.80 0.55
Ongoing CHD 0.92 0.55
Stroke initial event 0.63 0.52
Ongoing stroke 0.65 0.52
Diabetes mellitus 0.90 0.70
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Comparison of results
Table 42 shows the baseline results from Pavey et al.11 and the deterministic results from the adapted
model with the same RR used by Pavey et al.11 The Pavey et al.11 model has a smaller incremental cost but
gains 2.7 times the number of QALYs, resulting in an ICER of around £21,000.
Number of events avoided and quality-adjusted life-years gained
The number of events avoided and the QALYs gained reported by Pavey et al. and from the updated
model are shown in Table 43. Exercise referral avoids far more CHD, stroke and diabetes mellitus cases in
the Pavey et al.11 model than in the updated model, thus resulting in much a higher incremental QALY
gain in the Pavey et al. model. The difference in event rates is related to the differences in the duration of
the protective effect of physical activity and the strength of this protective effect.
TABLE 41 Comparison of estimated lifetime costs for patients entering a disease health state for the model
reported by Pavey et al.11 and the updated model
Parameter Pavey model lifetime costs (£) Updated model lifetime costs (£)
CHD 18,857 8953
Stroke 2090 21,101
Diabetes mellitus 53,512 10,392
TABLE 42 Baseline results from Pavey et al.11 and the updated model
Updated ERS model Mean cost (£) Mean QALY Incremental cost (£) Incremental QALY ICER (£)
ERS 4572 18.137 226 0.003 88,742
Usual care 4346 18.134 – – –
Pavey et al.11 model – – – – –
ERS 2492 16.743 169 0.008 20,876
Usual care 2322 16.735 – – –
Any inconsistencies in the ICERs presented here and those calculated from the presented incremental results area result of
decimal rounding.
TABLE 43 Comparison of number of events avoided
Event Pavey et al.11 Updated model
CHD 51 12.6
Stroke 16 6.1
Diabetes mellitus 86 9.6
QALYs gained 800 476
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Discussion
There are several limitations to the analysis based on the updated model. The model only estimates the
impact of physical activity on selected morbidities and the cost-effectiveness of ERSs may therefore be
underestimated. It is possible that there is a benefit from physical exercise on other morbidities, but
previous modellers have been unable to find the necessary data.11 The updated model does not include
the impact of adverse events or injuries; however, previous authors have commented that they are rare
events and are unlikely to affect the results.11
A limitation in assessing subgroups (obesity, hypertension and depression) is that, with the exception of
the depression subgroup, the efficacy of ERSs is assumed to be the same as the whole inactive population.
Further data would be needed on the efficacy of ERSs in these subgroups to test this assumption. The
model also assumes that the starting utility for these subgroups is the same as the general population.
If the starting utility were found to be lower in any of these subgroups, this may have the effect of
lowering the incremental QALY gains, resulting in a higher ICER than that generated within our
sensitivity analysis.
We were unable to assess whether or not less-intensive ERSs could be effective at a lower cost and
therefore be cost-effective. The sensitivity analysis indicated that schemes would need a 60% reduction in
costs to achieve an ICER below £30,000 per QALY gained. However, less-intensive schemes may be less
effective and so data on effectiveness and costs would be required to assess cost-effectiveness. (This issue
is explored in more detail in Appendix 7.)
The very small incremental QALYs gained by ERSs mean that the results are very sensitive to small changes
in some of the model parameters. A relatively small increase in the efficacy of ERSs or a 3-year increase in
the length of the process utility gain both lead to ICERs that are below £30,000 per QALY gained. In
contrast, removing the process utility attributed to ERSs results in an ICER in excess of £180,000 per QALY
gained, and using efficacy data from the ITT analysis, which provides a more conservative estimate of
effectiveness (RR 1.08, 95% CI 1.00 to 1.17), resulted in an ICER of around £114,000.
The ICER estimated by Pavey et al.11 was much lower than that estimated in the present analysis. However,
we found that several parameter changes reduced the ICER, and it was particularly sensitive to changes
in the duration over which the process utility was applied. It may be the case that minor changes to a
combination of parameter values (i.e. process utility, length of protective effect, RR of developing the
disease and the utility values) would bring the ICER down to a value more consistent with that estimated
by Pavey et al.11 (This supposition is explored in more detail in Appendices 6 and 7.)
Owing to time and data constraints, we were unable to model separately individuals with a pre-existing
condition and also those considered to be healthy. The model therefore assumes that patients do not have
CHD, stroke or type 2 diabetes mellitus at the start of the model. Although the population of interest for
the report as a whole includes those with a pre-existing medical condition, the economic analysis focuses
on a cohort without any of these three specific conditions. We have conducted subgroup analyses for
individuals who have hypertension, obesity or depression at the start of the model, as these subgroups
were already specified within the existing model. However, subgroup-specific effectiveness data were only
available for the depression subgroup.
The model oversimplifies the clinical situation because it does not recognise that more than one of the
three conditions can be present in the same individual and also that the presence of one comorbidity may
impact the likelihood of experiencing another. Again, we are constrained here to using an existing
economic model in which type 2 diabetes mellitus, CHD and stroke are treated as mutually exclusive
conditions. Also, the model does not account for the fact that stroke patients are at a higher risk of having
recurrent strokes and thus the utility loss and additional costs associated with this are not taken into
account. The impact of these limitations on the cost-effectiveness of ERSs is difficult to estimate.
DOI: 10.3310/hta19600 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 60
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Campbell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
Given that the effectiveness estimates applied in the model are based on data from a 1-year follow-up,
good-quality data on the sustainability of activity levels would lessen the uncertainty in the model that
comes from extrapolating from short- to long-term outcomes.
Conclusion
Our analysis indicates that the ICER for ERSs compared with usual care is around £76,000 per QALY,
although the cost-effectiveness of ERSs is subject to considerable uncertainty and is particularly sensitive to
the assumptions made regarding the effectiveness of ERSs in increasing physical activity and the size and
duration of process utility gains.
ASSESSMENT OF COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
Chapter 5 Discussion
Statement of principal findings
Systematic review of exercise referral schemes
This is an update of an existing review,11 and, therefore, this review uses the search results, data extraction
tools, data and findings of that review in this update. One additional RCT,31 additional qualitative data49
and two additional observational studies36,48 have been included in this update.
A total of eight RCTs14,17,21,22,28,32–34 met the inclusion criteria and were included in the review. Six
RCTs14,17,21,28,32,33 compared ERSs with usual care, which in all cases included some sort of advice regarding
physical activity. Two RCTs21,34 compared an alternative physical activity-promoting intervention and one
RCT31 compared an alternative form of ERS (i.e. ERS plus SDT intervention) with usual care.
There was considerable heterogeneity in the nature of the exercise/physical activity intervention across
studies. Studies recruited predominantly sedentary middle-aged adults who had evidence of at least
one lifestyle risk factor, and five of the studies also included individuals with a medical diagnosis (e.g.
hypertension, depression). ERSs usually took place at a leisure centre and involved 10–12 weeks of exercise
intervention and where there was follow-up it took place at 6 and/or 12 months post randomisation.
Studies were judged to have a moderate or low overall risk of bias.
The most commonly reported outcome was self-reported physical activity. When compared with usual
care, there was weak evidence of an increase in the number of ERS participants who achieved
90–150 minutes of at least moderate-intensity physical activity per week at 6–12 months’ follow-up
(pooled RR 1.12, 95% CI 1.04 to 1.20). There was no difference in physical activity between ERSs versus
alternative physical activity promotion interventions or ERSs versus ERSs plus SDT at 6–12 months’ follow-up.
We found no evidence to support differences across subgroups (e.g. age, sex) in terms of the impact
of ERSs on physical activity. Murphy et al.32 found that the intervention was effective in increasing levels of
physical activity in those referred for a CHD risk factor. There was no consistent evidence for a difference
between ERS and any of the comparator groups in the duration of moderate/vigorous intensity and total
physical activity, physical fitness, blood pressure, serum lipids, glycaemic control, obesity indices (body weight,
BMI, percentage fat), respiratory function, psychological well-being (perception of self-worth, or symptoms of
depression or anxiety) or HRQoL.
We found considerable variation across studies in the level of uptake (i.e. attendance at the first induction
visit) and adherence to ERSs (i.e. completion of the programme) across the 19 included studies
(16 observational studies and six RCTs). Uptake levels were higher, on average, in RCTs than in
observational studies, although there was no clear difference in adherence between the two. In bivariate
and multivariate analyses, women and older people were more likely to take up ERS. In addition, although
older people were also more likely to adhere, women were less likely to adhere than men. Very few
studies reported associations between ERS uptake or adherence and participant psychosocial factors or
programme-level predictors.
A consistent finding in the quantitative studies reporting adherence and uptake is the association between
increasing age and likelihood of uptake and adherence to ERS. This reverses the trend seen in the general
population, which is a decrease in physical activity with advancing age. A number of factors have been
proposed to explain this including that older people are less time-constrained, are more likely to value the
social interaction offered by the group-based approaches and may find it easier to incorporate the scheme
exercise activities (such as walking, swimming and cycling) into their everyday life. The only group to show
a statistically significant increase in physical activity in the Murphy et al.23 study were those referred for
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CHD risk. This group would also have been likely to have been older. Increasing age or CHD risk factors
may be confounding factors. It may be that these factors work in a complementary manner, with physical
activity perceived to be a means of reducing CHD risk and CHD risk a perceived greater threat to those of
advancing age.
One issue that may impact on trial results, as suggested in the qualitative review of discussion sections of
included trials, is the possibility that those volunteering to participate in the trial in the first place may have
been more motivated to become active or increase their physical activity. This may have contributed to the
overall finding that physical activity levels increased in both intervention and comparison groups. It is
therefore possible that trial participants (and perhaps also ERS participants in general) may be more
intrinsically motivated initially to become physically active and thus may differ from the population as a
whole in terms of their response to such a programme; according to SDT,71 intrinsic motivation is more
likely to lead to behaviour change that is maintained over the longer term. Therefore, ERSs may be
inadvertently creating inequality in service delivery and failing to reach those most in need of intervention,
through the element of self-selection that could creep in in terms of uptake and adherence to the scheme.
In two recent systematic reviews (Orrow et al.72 and Campbell et al.70) exploring the effectiveness of advice
or counselling delivered by health professionals within primary care to promote physical activity, positive
benefits were seen with significant increases in self-reported physical activity at 12 months. In Campbell
et al. where interventions were limited to brief advice the RR was 1.30 (CI 95% 1.12 to 1.50), favouring
brief advice over usual care. Neither review found any evidence to support ERS over advice or
counselling interventions.
This review did find benefit of ERSs over simply giving advice to promote physical activity. In all of the
control groups, advice was given on the value of increasing levels of physical activity. This may have had
the effect of reducing the apparent effectiveness of ERSs if compared with usual care which might mean
no advice to promote levels of physical activity. The quality of advice may not have been as high as that
delivered in the brief intervention studies, hence a difference was found between the effectiveness of ERS
schemes and advice alone. The presence of bias may also influence the findings in these studies, of which
only two22,32 attempted to blind at outcome assessment.
Strengths and limitations of the assessment
Clinical effectiveness
The strength of this update review is that it was able to use the robust findings of a previous systematic
review.11 The additional data included in this update supported the existing findings.
A rigorous search was carried out to identify any additional RCTs and qualitative studies done alongside
the RCTs (sibling studies). The narrow focus of this review in terms of its definition of ERSs meant that
similar interventions which may have yielded valuable insights were excluded from the review.
Measuring physical activity by methods of self-report has an obvious risk of self-report bias. There is no
gold standard self-reporting measure of adherence to physical activity or physical activity levels. Many
traditional instruments have shortcomings from a clinical perspective. Physical activity levels are often
scored on scales that are not easily converted into a counselling message. It can also be difficult to assess
small but clinically significant changes in physical activity levels in a practice situation. Problems with these
instruments underscore the challenge of translating research findings into clinical practice. Self-report levels
of physical activity are the only outcomes that show a significant effect. The reliance on outcomes that are
subject to recall bias is a weakness of this review.
Cost-effectiveness
The scope for the economic analysis of ERSs for this brief report was to update the Anokye et al.53 brief
advice model, with evidence from the updated systematic review on the effectiveness of ERS, and to
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update the costs. As such, we did not conduct a systematic review of the existing evidence on the
cost-effectiveness of ERSs, which limits our ability to place these results into a broader context. However,
we have conducted a detailed comparison with the model used by Pavey et al.11 to explore why the
ICERs differ so much from those previously reported. Several of the assumptions made in our economic
evaluation are more conservative than the assumptions made by Pavey et al.11 In particular, the restriction
of benefits to 10 years, which has had a substantial impact on the ICERs, may be considered to be a more
reasonable assumption than the lifetime benefits assumed by Pavey et al.11 (This issue is explored in
more detail in Appendix 6.)
The estimate of process utility gain associated with physical activity, which is a particularly important driver
of cost-effectiveness within the model, was based on cross-sectional data.11 It was included in our base
case analysis, as this was the approach taken in the economic evaluation of brief interventions to increase
physical activity,53 but was actually excluded from the base case analysis in the economic evaluation of ERSs
by Pavey et al.11 In our clinical effectiveness review, some but not all of the RCTs that reported HRQoL found
a statistically significant difference between ERSs and usual care, suggesting that this short-term benefit is
still relatively uncertain. (This issue is explored in more detail in Appendix 7.)
One of the main limitations of the economic evaluation is that it does not fully explore the potential for
cost-effectiveness to vary according to the exact nature of ERSs or the characteristics of the population to
whom it is offered. The cost of an ERS is likely to be highly dependent on the exact nature of that scheme.
The incremental cost is also dependent on the provision made to those who received usual care, which we
assumed to have zero cost. There was substantial variation in both of these factors across the included
studies, although our threshold analysis suggested that large changes in the incremental cost of ERS
compared with usual care would be needed to bring the ICER under £30,000. (This issue is explored in
more detail in Appendix 7.) Although we have provided some estimates of the cost-effectiveness of ERSs
for patients who might be referred for ERSs because of a pre-existing health condition, this has been
achieved by assuming that some data from the general population, such as the relative risks of being
physically active, are transferrable to those patients with pre-existing conditions.
Another key limitation of the model is that it only captures the impact of physical activity on three health
conditions and it does not allow for individuals to have multiple conditions. This fails to capture the many
aspects of health that may be influenced by physical activity and the complex relationships that exist between
different exercise-related conditions, such as the impact of type 2 diabetes mellitus on cardiovascular risk. In
addition, the model does not account for the fact that stroke patients are at a higher risk of having recurrent
strokes and, thus, the utility loss and additional costs associated with this are not taken into account.
The impact of these limitations on the cost-effectiveness of ERSs is difficult to estimate.
Uncertainties
Clinical effectiveness of exercise referral schemes
A number of uncertainties remain regarding the clinical effectiveness of ERSs:
l the potential value of different components of the ERS programme on promoting physical activity
l the long-term changes in physical activity behaviour as a result of participating in these schemes
l the extent to which people in the advice-only groups changed their levels of physical activity
l whether or not the small increases in self-reported physical activity are clinically significant or lead to
clinical significant differences.
Cost-effectiveness of exercise referral schemes
Good-quality data on the sustainability of activity levels, and the magnitude and sustainability of any
associated process utility gains, would lessen the uncertainty in the model.
DOI: 10.3310/hta19600 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 60
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Campbell et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
77

Chapter 6 Conclusions
Implications for service provision
In 2006, NICE commented that there is insufficient evidence for ERS and recommended that the NHS
should make ERS available only as part of a controlled trial. Pavey et al.11 updated the evidence available
with the inclusion of four additional trials and also concluded that there remains very limited support for
the potential role of ERSs in positively improving levels of physical activity. There was little evidence that
interventions incorporated strategies that enabled participants to achieve a sustainable active lifestyle, and
very little reference to the development of theoretically based interventions that draw on successful
behaviour-change techniques. This update supports and reinforces these findings. The additional data from
a large well-designed trial, conducted in the UK, which incorporated motivational interviewing, found that
ERSs improved levels of physical activity, but this was of borderline statistical significance.
Suggested research priorities
l The findings from both the quantitative and qualitative data suggest that referral for CHD risk and
increasing age are stronger predictors both for uptake and adherence to ERSs. Interventions targeting
older patients, at greater risk of reduced levels of physical activity and with CHD risk, may show greater
benefit of ERS. This should be further tested in mixed-method evaluation, incorporating both RCT
evidence and qualitative data, which will enable exploration of the elements of the intervention that
are most effective.
l Further research is needed to identify the mediating factors that influence uptake and adherence, with
a greater understanding of who benefits and in which circumstances. Fewer men take up ERSs. Studies
that explore the barriers and facilitators that men face in increasing levels of physical activity need to
be explored.
l Longitudinal studies that examine the relationship between increased levels of physical activity and
impact on health outcomes should be developed.
l Further research is needed to explore the effect of interventions with a theoretical basis and the fidelity
of the intervention with that theory.
l An understanding of the impact of advice in the control interventions which may have reduced the
impact of ERSs in studies in which it is compared with an advice-only group would be beneficial.
l Trials should be developed with a comparator group which addresses a different health behaviour or
an intervention for something unrelated (e.g. singing in choirs) that may also have a social benefit to
compare with ERS. Consider funding of three-arm trials or multiple comparison design trials so that the
impact of advice only can be controlled for.
l Adherence to ERSs, as measured by attendance, is only a proxy marker of exercise adherence,
particularly as participants are unlikely to adhere to the recommended exercise level by attending
one session per week. Further research is required to establish better methods of assessing
exercise adherence.
l Expected value of sample information techniques should be used to estimate whether or not the
benefits of conducting further research into the areas identified above, to reduce decision uncertainty
and potentially make different recommendations regarding the use of ERSs, would outweigh the cost
of conducting that additional research. The existing model could be used as a starting point for that
analysis, although it would need to be adapted to ensure that the structural uncertainties identified in
this report are reflected within the expected value of sample information in addition to the parameter
uncertainty currently included in the PSA.
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Appendix 1 Literature search strategies
Searches were limited by English language and publication date of October 2009 to present(8 May 2013 for stage 1 and 17 June 2013 for stage 2).
Stage 1 search
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and
Ovid MEDLINE(R) <1946 to present>
Search strategy
1. physical activity referral*.ti,ab.
2. exercise on prescription.ti,ab.
3. exercise referral*.ti,ab.
4. supervised exercise.ti.
5. 1 or 2 or 3 or 4
Stage 2 search
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and
Ovid MEDLINE(R) <1946 to present>
Search strategy
1. “Referral and Consultation”/
2. (exercise* or physical*).ti,ab.
3. 1 and 2 (2396)
4. ((physical* or exercise*) adj2 (superv* or subsid* or prescrib*)).ti,ab.
5. (exercise* adj2 (fit* or train* or activit* or promot* or program* or intervention*)).ti,ab.
6. (physical* adj2 (fit* or train* or activit* or promot* or program* or intervention*)).ti,ab.
7. ((physical* or exercise*) and referral*).ti,ab.
8. 4 or 5 or 6 or 7
9. Randomized controlled trial.pt.
10. Randomized Controlled Trial/
11. (random$ or placebo$).ti,ab,sh.
12. ((singl$ or double$ or triple$ or treble$) and (blind$ or mask$)).tw,sh.
13. 9 or 10 or 11 or 12
14. controlled clinical trial.pt.
15. (retraction of publication or retracted publication).pt.
16. 13 or 14 or 15
17. (family medicine$ or family practice$ or general practice$ or primary care or primary health care or
primary health service$ or primary healthcare or primary medical care or family medical practice$ or
family doctor$ or family physician$ or family practitioner$ or general medical practitioner$ or general
practitioner$ or local doctor$).ti,ab.
18. Family Practice/
19. Primary Health Care/
20. Physicians, Family/
21. Community Health Centers/
22. (community healthcare or community health care).ti,ab.
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23. (GP or GPs).ti,ab.
24. general practic*.ti,ab.
25. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. (referral* or promot* or program* or intervent*).ti,ab.
27. 25 or 26
28. Exercise/
29. Exercise Therapy/
30. 28 or 29
31. 27 and 30
32. 3 or 8 or 31
33. (child* or adolescent* or school* or pediatric* or paediatric*).ti.
34. 32 not 33
35. 16 and 34
36. (animals not humans).sh.
37. 35 not 36
38. (“2009 October*” or “2009 November*” or “2009 December*” or “2010*” or “2011*” or
“2012*” or “2013*”).dp.
39. 37 and 38
40. limit 39 to english language
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Appendix 2 Table of excluded studies with
rationale
TABLE 44 Full-text exclusion from all systematic review (electronic literature search)
Paper Comment
Ackermann RT, Deyo RA, LoGerfo JP. Prompting primary providers to increase community
exercise referrals for older adults: a randomized trial. J Am Geriatr Soc 2005;53:283–9
Randomisation before
baseline assessment
Anokye NK, Trueman P, Green C, Pavey TG, Hillsdon M, Taylor RS, et al. The
cost-effectiveness of exercise referral schemes. BMC Public Health 2011;11:954
Cost-effectiveness model
Baker M. Exercise Scheme Guidelines. Analysis. Practice Nurse 2001;21:14 Not a RCT
Beynon CM, Luxton A, Whitaker R, Cable NT, Frith L, Taylor AH, et al. Exercise
referral for drug users aged 40 and over: results of a pilot study in the UK. BMJ Open
2013;3:e002619
Not a RCT
Bull FC, Milton KE. A process evaluation of a “physical activity pathway” in the primary
care setting. BMC Public Health 2010;10:463
Not a RCT
Casey D, De CM, Dasgupta K, Casey D, De Civita M, Dasgupta K. Understanding physical
activity facilitators and barriers during and following a supervised exercise programme in
Type 2 diabetes: a qualitative study. Diabet Med 2010;27:79–84
Not a RCT
Chambers MJ. Exercise: a prescription for a good night’s sleep? Phys Sportsmed
1991;19:106–12
Not a RCT
Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical
activity: a modelling study. PLOS Med 2009;6:e1000110
Cost-effectiveness model
Corbett C, Woodiwiss B. Exercise on prescription. Professional Nurse 1900;18:666–7 Not a RCT
Davies T, Craig A. Developments & opportunities for exercise prescription . . . This article is
the first in a series focussing on issues in exercise prescription. SportEX Medicine
1999;1:20–2
Not a RCT
Dugdill L, Graham RC, McNair F. Exercise referral: the public health panacea for physical
activity promotion? A critical perspective of exercise referral schemes; their development
and evaluation. Ergonomics 2005;48:1390–410
Not a RCT
Elley CR, Garrett S, Rose SB, O’Dea D, Lawton BA, Moyes SA, et al. Cost-effectiveness of
exercise on prescription with telephone support among women in general practice over
2 years. BJSM Online 2011;45:1223–9
No primary care referral
Elley CR, Kerse N, Arroll B, Robinson E. Effectiveness of counselling patients on physical
activity in general practice: cluster randomised controlled trial. Br Med J 2003;326:793–6
No third-party exercise
provider
Gademan MG, Deutekom M, Hosper K, Stronks K, Gademan MGJ, Deutekom M, et al.
The effect of exercise on prescription on physical activity and wellbeing in a multi-ethnic
female population: a controlled trial. BMC Public Health 2012;12:758
Not a RCT
Gidlow C, Johnston LH, Crone D, Morris C, Smith A, Foster C, et al. Socio-demographic
patterning of referral, uptake and attendance in Physical Activity Referral Schemes.
J Public Health (Oxf) 2007;29:107–13
Not a RCT
Graham RC, Dugdill L, Cable NT. Health practitioner perspectives in exercise referral:
implications for the referral process. J Sports Sci 2005;24:636–7
Not a RCT
Grandes G, Sanchez A, Sanchez-Pinilla RO, Torcal J, Montoya I, Lizarraga K, et al.
Effectiveness of physical activity advice and prescription by physicians in routine primary
care: a cluster randomized trial. Arch Intern Med 2009;169:694–701
No primary care referral
Hardcastle S, Taylor A, Bailey M, Castle R. A randomised controlled trial on the
effectiveness of a primary health care based counselling intervention on physical activity,
diet and CHD risk factors. Patient Educ Couns 2008;70:31–9
No primary care referral
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TABLE 44 Full-text exclusion from all systematic review (electronic literature search) (continued )
Paper Comment
Harland J, White M, Drinkwater C, Chinn D, Farr L, Howel D. The Newcastle exercise
project: a randomised controlled trial of methods, to promote physical activity in primary
care. Br Med J 1999;319:828–32B
No primary care referral
Hellenius M-L. Prescribing exercise in clinical practice. Curr Cardiovasc Risk Rep
2011;5:331–9
Not a RCT
Jebb SA, Ahern AL, Olson AD, Aston LM, Holzapfel C, Stoll J, et al. Primary care referral
to a commercial provider for weight loss treatment versus standard care: a randomised
controlled trial. Lancet 2011;378:1485–92
No third-party exercise
provider
Johnston LH, Warwick J, De Ste CM, Crone D, Sidford A. The nature of all ‘inappropriate
referrals’ made to a countywide physical activity referral scheme: implications for practice.
Health Educ J 2005;64:58–69
Not a RCT
Jolly K, Daley A, Adab P, Lewis A, Denley J, Beach J, et al. A randomised controlled trial to
compare a range of commercial or primary care led weight reduction programmes with a
minimal intervention control for weight loss in obesity: the Lighten Up trial. BMC Public
Health 2010;10:439
No third-party exercise
provider
Josyula LK. Examination of physical activity for health promotion, and attitudes towards
aging, among adults – cross-cultural comparisons; healthcare provider recommendations;
toolkit evaluation. Dissertation Abstracts International: Section B: The Sciences and
Engineering 1942;71(7-B)
Not a RCT
Karjalainen JJ, Kiviniemi AM, Hautala AJ, Niva J, Lepojarvi S, Makikallio TH, et al. Effects
of exercise prescription on daily physical activity and maximal exercise capacity in coronary
artery disease patients with and without type 2 diabetes. Clin Physiol Funct Imaging
2012;32:445–54
No third-party exercise
provider
Kolt GS, Schofield GM, Kerse N, Garrett N, Ashton T, Patel A, et al. Healthy Steps trial:
pedometer-based advice and physical activity for low-active older adults. Ann Fam Med
2012;10:206–12
Not appropriate population
Kolt GS, Rosenkranz RR, Savage TN, Maeder AJ, Vandelanotte C, Duncan MJ, et al.
WALK 2.0 – Using Web 2.0 applications to promote health-related physical activity:
a randomised controlled trial protocol. BMC Public Health 2013;13:436
No primary care referral
Lawton BA, Rose SB, Elley CR, Dowell AC, Fenton A, Moyes SA. Exercise on prescription
for women aged 40–74 recruited through primary care: two year randomised controlled
trial. BMJ 2008;337:a2509
No primary care referral
Lawton BA, Rose SB, Raina EC, Dowell AC, Fenton A, Moyes SA, et al. Exercise on
prescription for women aged 40–74 recruited through primary care: two year randomised
controlled trial. BJSM Online 2009;43:120–3
No primary care referral
Lawton BA. Exercise on prescription for women aged 40–74 recruited through primary
care: two year randomised controlled trial. BMJ 2009;339:a2509
No primary care referral
Leung W, Ashton T, Kolt GS, Schofield GM, Garrett N, Kerse N, et al. Cost-effectiveness
of pedometer-based versus time-based Green Prescriptions: the Healthy Steps Study.
Aust J Prim Health 2012;18:204–11
No primary care referral
Lord JC, Green F. Exercise on prescription: does it work? Health Educ J 1995;54:453–64 Not a RCT
Markland D, Tobin VJ. Need support and behavioural regulations for exercise among
exercise referral scheme clients: The mediating role of psychological need satisfaction.
Psychol Sport Exerc 2010;11:91–9
Not a RCT
Mckay J, Wright A, Lowry R, Steele K, Ryde G, Mutrie N. Walking on prescription:
The utility of a pedometer pack for increasing physical activity in primary care. Patient
Educ Couns 2009;76:71–6
No primary care referral
Mills H, Crone D, James DV, Johnston LH, Mills H, Crone D, et al. Exploring the
perceptions of success in an exercise referral scheme: a mixed method investigation.
Eval Rev 2012;36:407–29
Not a RCT
Murphy MH, McNeilly AM, Murtagh EM. Physical activity prescription for public health.
Proc Nutr Soc 2010;69:178–84
Not a RCT
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TABLE 44 Full-text exclusion from all systematic review (electronic literature search) (continued )
Paper Comment
Mutrie N, Doolin O, Fitzsimons CF, Grant PM, Granat M, Grealy M, et al. Increasing older
adults’ walking through primary care: results of a pilot randomized controlled trial.
Fam Pract 2012;29:633–42
No primary care referral
Nicolai SPA, Kruidenier LM, Leffers P, Hardeman R, Hidding A, Teijink JAW, et al.
Supervised exercise versus non-supervised exercise for reducing weight in obese adults.
J Sports Med Phys Fitness 2009;49:85–90
No primary care referral
Orrow G, Kinmonth AL, Sanderson S, Sutton S. Republished research: effectiveness of
physical activity promotion based in primary care: systematic review and meta-analysis of
randomised controlled trials. BJSM Online 2013;47:27
Not a RCT
Phillips EM, Kennedy MA. The exercise prescription: a tool to improve physical activity.
PM&R 2012;4:818–25
Not a RCT
Pringle A, Gilson N, McKenna J, Cooke C. An evaluation of the Local Exercise Action
Pilots and impact on moderate physical activity. Health Educ J 2009;68:179–85
Not a RCT
Pugh D. Time to encourage patients to take more exercise. The Practitioner 2012;256:25–8 Not a RCT
Richards J, Foster C, Thorogood M, Hillsdon M, Kaur A, Wickramasinghe KK, et al.
Face-to-face interventions for promoting physical activity. Cochrane Database Syst Rev
2013;9:CD010392
Not a RCT
Rimer J, Dwan K, Lawlor DA, Greig CA, McMurdo M, Morley W, et al. Exercise for
depression. Cochrane Database Syst Rev 2012;7:CD004366
Not a RCT
Rouse PC, Ntoumanis N, Duda JL, Jolly K, Williams GC, Rouse PC, et al. In the beginning:
role of autonomy support on the motivation, mental health and intentions of participants
entering an exercise referral scheme. Psychol Health 2011;26:729–49
Not a RCT
Rome A, Persson U, Ekdahl C, Gard G. Physical activity on prescription (PAP): costs and
consequences of a randomized, controlled trial in primary healthcare. [Provisional
abstract]. Scand J Prim Health Care 2009;27:216–22
Part of intervention prior to
randomisation
Sabti Z, Handschin M, Joss MK, Allenspach EC, Nuscheler M, Grize L, et al. Evaluation of
a physical activity promotion program in primary care. Fam Pract 2010;27:279–84
Not a RCT
Santos C, Santos J, Morais L, Rodrigues F, Barbara C. Pulmonary rehabilitation in COPD:
effects of two aerobic exercise intensity in patient-centered outcomes – a randomized
study. [Abstract]. Chest 2011;140:853A
No primary care referral
Slade SC, Keating JL. Effects of preferred-exercise prescription compared to usual exercise
prescription on outcomes for people with non-specific low back pain: a randomized
controlled trial [ACTRN12608000524392]. BMC Musculoskelet Disord 2009;10:14
No primary care referral
Slade SC, Keating JL. Exercise prescription: a case for standardised reporting. BJSM Online
2012;46:1110
Not a RCT
Sorensen J, Sorensen JB, Skovgaard T, Bredahl T, Puggaard L, Sorensen J, et al. Exercise
on prescription: changes in physical activity and health-related quality of life in five Danish
programmes. Eur J Public Health 2011;21:56–62
Not a RCT
Sukala WR, Page R, Cheema BS, Sukala WR, Page R, Cheema BS. Exercise training in
high-risk ethnic populations with type 2 diabetes: a systematic review of clinical trials.
Diabetes Res Clin Pract 2012;97:206–16
Not a RCT
Taylor TR, Makambi K, Sween J, Roltsch M, Adams-Campbell LL, Taylor TR, et al. The
effect of a supervised exercise trial on exercise adherence among African American Men:
a pilot study. J Natl Med Assoc 2011;103:488–91
Not a RCT
Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Roseboom T, Tomlinson JW, et al.
Effects of interventions in pregnancy on maternal weight and obstetric outcomes:
meta-analysis of randomised evidence. BMJ 2012;344:e2088
Not a RCT
Thangaratinam S, Rogozinska E, Jolly K, Glinkowski S, Duda W, Borowjack E, et al.
Interventions to reduce or prevent obesity in pregnant women: A systematic review.
Health Technol Assess 2012;16(31)
Not a RCT
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TABLE 44 Full-text exclusion from all systematic review (electronic literature search) (continued )
Paper Comment
van Midde Koop M, Rubinstein SM, Verhagen AP, Ostelo RW, Koes BW, van Tulder MW.
Exercise therapy for chronic nonspecific low-back pain. Best Pract Res Clin Rheumatol
2010;24:193–204
Not a RCT
van Hoecke AS, Delecluse C, Bogaerts A, Boen F. The long-term effectiveness of
need-supportive physical activity counselling compared with a standard referral in
sedentary older adults. J Aging Phys Activity 2015: in press
No primary care referral
Vermunt PW, Milder IE, Wielaard F, de Vries JH, Baan CA, van Oers JA, et al. A lifestyle
intervention to reduce Type 2 diabetes risk in Dutch primary care: 2.5-year results of a
randomized controlled trial. Diabet Med 2012;29:e223–31
No primary care referral
Vermunt PW, Milder IE, Wielaard F, de Vries JH, van Oers HA, Westert GP, et al. Lifestyle
counselling for type 2 diabetes risk reduction in Dutch primary care: results of the
APHRODITE study after 0.5 and 1.5 years. Diabetes Care 2011;34:1919–25
No primary care referral
Voet NB. Strength training and aerobic exercise training for muscle disease. Cochrane
Database Syst Rev 2010;1:CD003907
Not a RCT
Voet NB, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BG, Geurts AC, et al.
Strength training and aerobic exercise training for muscle disease. [Update of Cochrane
Database Syst Rev 2005;1:CD003907; PMID: 15674918]. Cochrane Database Syst Rev
2010;1:CD003907
Not a RCT
Ward M, Phillips CJ, Farr A. Heartlinks – a real world approach to effective exercise
referral. Int J Health Promo Educ 2010;48:20–7
Not a RCT
Waryasz GR, McDermott AY. Exercise prescription and the patient with type 2 diabetes:
A clinical approach to optimizing patient outcomes. J Am Acad Nurse Pract
2010;22:217–27
Not a RCT
Wu YT, Hwang CL, Chen CN, Chuang LM, Wu YT, Hwang CL, et al. Home-based
exercise for middle-aged Chinese at diabetic risk: a randomized controlled trial. Prev Med
2011;52:337–43
No primary care referral
Wyatt-Williams J. Setting up a national exercise referral scheme (in Wales). J Aging Phys
Activ 2012;20:S259
Not a RCT
Yildirim Y, Soyunov S. Relationship between learning strategies of patients and proper
perception of the home exercise program with non-specific low back pain. J Back
Musculoskeletal Rehabil 2010;23:137–42
No primary care referral
Yoshida H, Ishikawa T, Suto M, Kurosawa H, Hirowatari Y, Ito K, et al. Effects of
supervised aerobic exercise training on serum adiponectin and parameters of lipid and
glucose metabolism in subjects with moderate dyslipidemia. J Atheroscler Thromb
2010;17:1160–6
Not a RCT
Zanuso S, Jimenez A, Pugliese G, Corigliano G, Balducci S, Zanuso S, et al. Exercise
for the management of type 2 diabetes: a review of the evidence. Acta Diabetol
2010;47:15–22
Not a RCT
Zhang XD, Long BB, Wu H. Effects of aerobic exercise prescription intervention to female
college students with simple obesity. Proceedings of the 21st Pan-Asian Congress of
Sports and Physical Education, Application of Physiology and Psychology in Sports
2010;4:87–9
No primary care referral
Zuazagoitia A, Grandes G, Torcal J, Lekuona I, Echevarria P, Gomez MA, et al. Rationale
and design of a randomised controlled trial evaluating the effectiveness of an exercise
program to improve the quality of life of patients with heart failure in primary care:
The EFICAR study protocol. BMC Public Health 2010;10:33
No third-party exercise
provider
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Appendix 3 Inputs for probabilistic sensitivity
analysis
TABLE 45 Inputs for probabilistic sensitivity analysis
Parameter Mean Standard error Distribution
Incidence rates for
CHD (available by age groups, years)
33–34 0.000035 1.0881E-05 Beta
35–44 0.000465 3.9654E-05
45–54 0.002095 8.41E-05
55–64 0.00631 0.00014565
65–74 0.0097 0.00018027
75–81 0.0097 0.00018027
Stroke (available by age groups, years)
33–34 0.00008 2.7602E-05 Beta
35–44 0.00023 4.6797E-05
45–54 0.00057 7.3658E-05
55–64 0.00291 0.00016623
65–74 0.0069 0.00025546
75–81 0.01434 0.0003669
Diabetes mellitus (available by age groups, years)
33–39 9.00365E-05 6.9895E-06 Beta
40–49 0.000280353 1.2332E-05
50–59 0.000631793 1.851E-05
60–69 0.001004529 2.3336E-05
70–79 0.001115584 2.459E-05
80–81 0.001115584 2.459E-05
Probability
Fatality cases for CHD
33–34 0.08773 0.008773 Beta
35–44 0.08773 0.008773
45–54 0.08773 0.008773
55–64 0.11553 0.011553
65–74 0.21065 0.021065
75–81 0.14763 0.014763
Fatality cases for stroke
33–34 0.234636872 0.02346369 Beta
35–44 0.234636872 0.02346369
45–54 0.234636872 0.02346369
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TABLE 45 Inputs for probabilistic sensitivity analysis (continued )
Parameter Mean Standard error Distribution
55–64 0.23279352 0.02327935
65–74 0.23466258 0.02346626
75–81 0.23420074 0.02342007
Relative risks for
Being active (at year 1) as a result of exercise referral 1.1 0.06 Log-normal
Developing disease conditions for active people
l CHD 0.90 0.04 Log-normal
l Stroke 0.86 0.04
l Type 2 diabetes mellitus 0.67 0.12
Non-CVD mortality after
Non-fatal CHD 1.71 0.14 Log-normal
Non-fatal stroke 1.71 0.14
Diabetes mellitus 1.49 0.13
CVD mortality after
Non-fatal CHD 3.89 0.04 Log-normal
Non-fatal stroke 3.89 0.04
Diabetes mellitus 2.61 0.14
Utility
Age (years)-specific QoL
45–54 0.86 0.01 Beta
55–64 0.82 0.01
65–74 0.78 0.01
75+ 0.72 0.01
Health state utility weight
Healthy 1.00 0.10 Gamma
CHD first event 0.80 0.08
Ongoing CHD 0.92 0.09
Stroke initial event 0.63 0.06
Ongoing stroke 0.65 0.07
Diabetes mellitus 0.90 0.09
Mental health gain 0.07 0.04 Beta
Cost
Exercise referral £229 £23 Normal
CHD first event £4198 £395
Ongoing CHD £480 £45
Stroke initial event £10,839 £1019
Ongoing stroke £2380 £224
Diabetes mellitus £968 £91
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Appendix 4 Mortality data
TABLE 46 Mortality data
Age (years) All-cause mortality CVD-cause mortality Non-CVD-cause mortality
50 0.002854 0.00054 0.00231
51 0.003087 0.00059 0.00250
52 0.003413 0.00065 0.00276
53 0.003693 0.00070 0.00299
54 0.004115 0.00078 0.00333
55 0.004513 0.00086 0.00366
56 0.004949 0.00094 0.00401
57 0.005334 0.00101 0.00432
58 0.005799 0.00110 0.00470
59 0.006403 0.00122 0.00519
60 0.006948 0.00132 0.00563
61 0.007478 0.00142 0.00606
62 0.008051 0.00153 0.00652
63 0.009034 0.00172 0.00732
64 0.010004 0.00190 0.00810
65 0.010801 0.00240 0.00840
66 0.011984 0.00266 0.00932
67 0.013043 0.00290 0.01015
68 0.014685 0.00326 0.01142
69 0.016104 0.00358 0.01253
70 0.017616 0.00391 0.01370
71 0.01932 0.00429 0.01503
72 0.021385 0.00475 0.01663
73 0.023881 0.00531 0.01858
74 0.026280 0.005838 0.020442
75 0.029173 0.007763 0.021410
76 0.032836 0.008737 0.024098
77 0.036376 0.009679 0.026696
78 0.040763 0.010847 0.029916
79 0.045782 0.012183 0.033600
80 0.051718 0.013762 0.037956
81 0.057861 0.015397 0.042465
82 0.064138 0.017067 0.047071
83 0.071322 0.018979 0.052343
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TABLE 46 Mortality data (continued )
Age (years) All-cause mortality CVD-cause mortality Non-CVD-cause mortality
84 0.080421 0.021400 0.059021
85 0.089901 0.023922 0.065978
86 0.099902 0.026584 0.073318
87 0.110316 0.029355 0.080961
88 0.122565 0.032614 0.089951
89 0.128800 0.034274 0.094527
90 0.143003 0.038053 0.104951
91 0.153263 0.040783 0.112480
92 0.175290 0.046644 0.128646
93 0.194175 0.051670 0.142505
94 0.214034 0.056954 0.157080
95 0.233037 0.062011 0.171026
96 0.251844 0.067015 0.184829
97 0.269651 0.071754 0.197898
98 0.290335 0.077258 0.213078
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Appendix 5 Data extraction
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Appendix 6 Additional analyses conducted prior
to the first committee meeting
Introduction
Prior to the first Committee meeting we were asked by the Centre for Public Health Practice to provide
some additional analyses to inform the Committee’s discussions. In particular we were asked to
provide additional analyses to support the following statement in Chapter 4, Discussion, ‘It may be the
case that minor changes to a combination of parameter values . . . would bring the ICER down to a value
more consistent with that estimated by Pavey et al.’11
Based on the univariate sensitivity analyses already conducted, it can be seen that the model is sensitive to
the duration of protective effect associated with physical activity for the conditions CHD, stroke and
diabetes. In the base case analysis, the duration of protective effect was limited to 10 years. However, the
RR estimates applied in the model were based on cohort studies with follow-up periods of 19 years for
CHD57 and stroke58 and 12 years for diabetes mellitus.59 We have, therefore, decided to explore the
possibility of extending the protective effect to reflect the durations of these studies.
The model is also particularly sensitive to the process utility gain attributable to becoming physically active.
In the base case analysis it is assumed that the process utility gain associated with physical activity is
applied for 1 year only, as this is the duration of follow-up for the effectiveness studies. Without studies
providing longer-term follow-up it is unclear how long people remain physically active. However, it is likely
that some people who continue to be physically active at 1 year will carry on being physically active in the
longer-term. To explore the impact of a gradual fall-off in the number remaining physically active, we have
applied the process utility for 10 years, but assumed a linear decrease in the number who are physically
active over those 10 years, such that none are receiving a process utility gain from being physically active
after 10 years.
We also explored the effect on the ICER of combining these two less-conservative assumptions regarding
the longer-term benefits of ERS.
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Results
Presented are deterministic results for the whole cohort eligible to receive ERSs for several scenarios
exploring less-conservative model assumptions.
Extending the duration of the protective effect associated with physical activity to 19 years for CHD and
stroke and 12 years for diabetes mellitus, to reflect the follow-up periods in the studies used to estimate
the RRs applied in the model, reduced the ICER to £50,634 as seen in Table 47.
Applying the process utility for 10 years but assuming a linear decrease in the number who are physically
active over those 10 years gave an ICER of £21,918, when all other assumptions were held constant, as
shown in Table 48.
Results when combining the extended duration of protective effect, with the gradual fall-off in the
proportion remaining active are presented in Table 49, which shows an ICER of £18,935.
The additional analyses conducted, which explore the effect on the ICER of applying some less-conservative
model assumptions, demonstrate that ICERs as low as £19,000 per QALY can be achieved by combining a
gradual fall-off in physical activity over 10 years and extending the duration of protective effect beyond
10 years. This supports the statement made in Chapter 4, Discussion that ‘It may be the case that minor
changes to a combination of parameter values . . . would bring the ICER down to a value more consistent
with that estimated by Pavey et al.’11
TABLE 47 Duration of protective effect extended to 19 years for CHD and stroke and 12 years for diabetes mellitus
Intervention Mean cost Mean QALY Incremental cost Incremental QALY ICER
ERS £4527 18.152 £221 0.004 £50,634
Usual care £4306 18.148 – – –
TABLE 48 Number remaining physically active falls linearly to zero over 10 years
Intervention Mean cost Mean QALY Incremental cost Incremental QALY ICER
ERS £4572 18.218 £225 0.010 £21,918
Usual care £4346 18.208 – – –
TABLE 49 Duration of protective effect extended and number remaining physically active falls linearly to zero
over 10 years
Intervention Mean cost Mean QALY Incremental cost Incremental QALY ICER
ERS £4527 18.234 £221 0.012 £18,935
Usual care £4306 18.222 – – –
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Appendix 7 Additional analyses conducted prior
to the second committee meeting
Introduction
Following the first PHAC on ERSs, NICE requested that ScHARR-TAG conduct additional analyses to inform
the Committee’s discussion at the second PHAC. Incremental cost-effectiveness ratios were requested for a
‘combined scenario analysis’ incorporating:
l costs for providing brief advice in the comparator arm
l efficacy estimates from the ITT analysis
l a 10-year linear fall-off in the process utility associated with being physical active, applied in
combination with the original base case assumption that the protective effects of exercise are limited
to 10 years.
It should be noted that the assumptions incorporated into this ‘combined scenario analysis’ requested by
NICE do not necessarily reflect the authors’ preferred model assumptions.
In addition, several sensitivity analyses were also requested in which individual changes were made to the
combined scenario analysis. First, a sensitivity analysis was requested exploring the impact of using EQ-5D
data from the Murphy et al.23 study as an alternative to the process utility gain estimated by Pavey et al.11
and applied in the model used to inform the PH44.65 Second, a sensitivity analysis was requested exploring
the cost-effectiveness of less-intensive ERSs. Finally, a threshold analysis was also requested on the
intervention cost for ERSs.
Further details on the methods used to conduct these analyses are provided in Methods, and the results
are presented in Results.
Methods
Incorporating costs for brief advice
In the main report it was noted that in all of the studies comparing exercise referral to usual care, patients
randomised to the usual-care arm received some form of advice regarding physical activity. In the model
used by Pavey et al.11 no cost was attributed to providing usual care in the comparator arm, which may
have overestimated the incremental cost of ERS relative to usual care. In the appraisal of brief advice to
promote physical activity, the cost of brief advice was estimated at £9.50 (2010/11 prices).65 This was
inflated to a 2011/12 cost of £9.81 using inflation indices from the PSS Research Unit71 and applied in the
combined scenario analysis presented below.
Intention-to-treat analysis
In the main report efficacy results were meta-analysed using two different approaches. In Figure 2 the
denominators used to calculate the RRs were the number of patients with data at follow-up for each
study, whereas in Figure 3, in order to assess the potential (attrition) bias in using completers, the
denominators of these three studies were adjusted to all individuals randomised in order to perform an
ITT analysis. The cost-effectiveness results presented in the main report used the efficacy data based
on individuals with follow-up (RR 1.12, 95% CI 1.04 to 1.20). In the combined scenario analysis presented
below we use the efficacy data based on the ITT analysis (RR 1.08, 95% CI 1.00 to 1.17).
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Duration of protective effect and process utility gain
In the model used to inform PH44,65 the protective effect of physical activity on stroke, type 2 diabetes
mellitus and CHD was assumed to last for 10 years and a process utility associated with being physically
active was assumed to apply for 1 year. In Appendix 6 we presented analyses exploring the impact of
increasing the assumed duration of protective effect and the assumed duration over which the process
utility is applied. In the combined scenario analysis presented, we assume that the duration of protective
effect is maintained at 10 years but that there is a linear fall-off in the process utility gain over this 10-year
period. This would be consistent with assuming that the number continuing to be physically active falls
linearly over the 10 years after the intervention and that the full process utility gain is experienced until the
individual stops being physically active.
Process utility gain
The process utility gain associated with being physically active reported by Pavey et al.,11 and applied in
the economic model used to inform PH44,65 is based on cross-sectional data and therefore may not
represent a causal relationship between physical activity and health utility. However, Murphy et al.23 report
EQ-5D utility scores at 12 months for patients randomised to ERSs and usual care, allowing the utility
gain attributable to ERSs to be calculated directly from a randomised comparison. Table 16 of the main
report presents the mean EQ-5D scores from the two trial arms as 0.64 [standard deviation (SD) 0.32,
n= 395] and 0.61 (SD 0.32, n= 391) for ERSs and usual care, respectively, giving a mean difference of
0.03 [standard error (SE)= 0.023]. It should be noted that this cannot be compared directly against the
process utility of 0.072 given by Pavey et al., as the value from Pavey et al. is an estimate of the difference
between those who are physically active and those who are not physically active, whereas the value from
Murphy et al.23 is the difference between the randomised groups, each of which had a different proportion
who became physically active.
In the additional sensitivity analysis reported below, we have removed the process utility gain of 0.072,
which was applied in the base case analysis to all those who were physically active at 1 year, and added
0.03 to the utility values for all those receiving ERS. Nothing is added to the utility values of those receiving
usual care, as this gain is measured relative to usual care. In this sensitivity analysis it is assumed that the
utility gain measured by Murphy et al.23 is experienced for only 1 year as this is the duration of study
follow-up. Although it may be assumed that the process utility gain of being physically active may extend
beyond the study duration, if people remain physically active, the utility gain associated with receiving ERS
is the average gain across those who become active and those who do not and, therefore, it cannot be
extrapolated in the same manner, as there is no rationale for a continued utility gain in those who received
ERS but did not become physically active.
Less-intensive exercise referral schemes
In this sensitivity analysis we considered how the cost-effectiveness of a less-intensive form of ERS might
differ from that assumed in the base case using evidence on a walking-based intervention (as opposed to a
structured leisure centre-based intervention) from Isaacs et al.18 This replicates a similar sensitivity analysis
conducted by Pavey et al.11 in which the intervention cost was reduced from £222 to £110. In our
sensitivity analysis, the cost of the walking-based intervention was inflated to a cost of £114 (2011/12)31 to
reflect current prices. We assumed that there was no change in efficacy associated with moving to a
less-intensive ERSs.
Threshold analysis on the intervention cost for exercise referral schemes
A threshold analysis was conducted in which the intervention cost for ERSs was lowered until the ICER
reached the £20,000 and £30,000 per QALY threshold boundaries, while holding constant all other data
and assumptions applied in the combined scenario analysis.
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Results
Main results for the cohort eligible to receive exercise referral schemes
The individual and combined effects of each of the changes to the model assumptions described in
Methods are presented in Table 50. It can be seen that the addition of costs for providing some brief
advice related to physical activity in the usual-care arm has little effect on the ICER. The application of the
ITT efficacy data does have a small effect on the incremental costs but a greater proportionate effect on
the incremental QALYs, resulting in a substantial increase in the ICER. Allowing for a 10-year linear
reduction in the proportion remaining active, and therefore accruing a process utility gain, results in a
substantial increase in incremental QALYs from 0.003 to 0.010 and results in the ICER falling to £21,918.
The combined effect of all of three changes to the previous base case gives an ICER of £31,081 for the
combined scenario analysis.
Table 51 shows the PSA results per individual for the combined scenario analysis estimated from 10,000
samples. The PSA results are very similar to the deterministic results, with an ICER of £31,009.
Figure 19 shows a cost-effectiveness plane of the probabilistic results for the first 1000 samples. The
cost-effectiveness acceptability curve in Figure 20 shows the probability that ERS is cost-effective at various
willingness-to-pay thresholds (estimated from the full 10,000 samples). The probability that ERS is
cost-effective compared with usual care is 0.41 for a willingness-to-pay threshold of £30,000 per QALY
gained and 0.15 for a willingness-to-pay threshold of £20,000 per QALY.
Subgroup analysis
The results for the subgroup analysis using the combined scenario analysis assumptions are presented in
Tables 52–55. When assuming that the effectiveness of ERSs in each of these subgroups is similar to that
in the eligible population as a whole, the ICERs are marginally more favourable than those of the whole
population because of the greater risks of conditions associated with inactivity in these subgroups.
However, applying the subgroup data for the depressed cohort from the Murphy et al. study resulted in a
much higher ICER which reflects the estimate of low efficacy for this subgroup within the study reported
by Murphy et al.23
TABLE 50 Individual and combined effects of revised model assumptions
Scenario Description
ERS Usual care Incremental
ICERCost QALYs Cost QALYs Cost QALYs
NA Previous base case £4572 18.136 £4346 18.133 £225 0.003 £76,059
1 Added cost of brief advice in the
usual-care arm
£4562 18.136 £4346 18.133 £216 0.003 £72,748
2 ITT RR £4573 18.135 £4346 18.133 £227 0.002 £113,931
3 10-year fall-off in process utility £4572 18.218 £4346 18.208 £225 0.010 £21,918
1+ 2+ 3 Combined scenario analysis £4563 18.216 £4346 18.209 £217 0.007 £31,081
TABLE 51 Probabilistic sensitivity analysis results for the combined scenario analysis
Intervention Mean cost (95% CI) Mean QALY (95% CI) Incremental cost Incremental QALY ICER
ERS £4559 18.2154 £217 0.0070 £31,009
Usual care £4343 18.2084 – – –
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TABLE 52 Obese cohort using base case RR for effectiveness of ERSs
Intervention Mean cost Mean QALY Incremental cost Incremental QALY ICER
ERS £4757 18.142 £213.8 0.008 £26,015
Usual care £4543 18.134 – – –
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FIGURE 19 Cost-effectiveness plane for the combined scenario analysis.
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FIGURE 20 Cost-effectiveness acceptability curve for the combined scenario analysis.
TABLE 53 Hypertensive cohort using base case RR effectiveness of ERSs
Intervention Mean cost Mean QALY Incremental cost Incremental QALY ICER
ERS £4624 18.191 £215.8 0.007 £29,056
Usual care £4408 18.183 – – –
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TABLE 54 Depressive cohort using Murphy et al. subgroup data for effectiveness of ERSs (Professor Simon Murphy,
personal communication)
Intervention Mean cost Mean QALY Incremental cost Incremental QALY ICER
ERS £4685 18.112 £218.0 0.002 £96,462
Usual care £4467 18.110 – – –
Additional sensitivity analyses
The sensitivity analysis in which the process utility gain for ERS versus usual care has been estimated
directly from the Murphy et al. study23 is reported in Table 56. The QALY gain is similar to that reported by
Murphy et al. (0.03),23 as it is largely driven by the utility gains derived during the 1-year trial period.
Compared with the combined scenario analysis which uses the process utility gain attributable to being
physically active, the QALY gain attributable to ERS is over three times greater (0.026 versus 0.007) when
estimated using this directly measured EQ-5D resulting in an ICER of £8290.
The sensitivity analysis applying costs from a less-intensive intervention to increase physical activity
(walking-based intervention) but assuming no change in efficacy from the combined scenario analysis is
reported in Table 57. It can be seen that this reduced the ICER by approximately one-half, as the
less-intensive walking-based intervention has approximately one-half of the cost of the structured leisure
centre-based intervention which was used to estimate the cost of ERS in the combined scenario analysis.
The results of the threshold analysis on the cost of ERS were as follows. A 4% reduction in the cost
of ERSs from £229 to £220 gave an ICER just under £30,000 per QALY when holding all other conditions
from the combined scenario analysis constant. A 36% reduction in the cost of ERSs from £229 to £147
gave an ICER just under £20,000 per QALY when holding all other conditions from the combined scenario
analysis constant.
TABLE 55 Depressive cohort using base case RR for effectiveness of ERSs
Intervention Mean cost Mean QALY Incremental cost Incremental QALY ICER
ERS £4681 18.119 £213.8 0.009 £23,903
Usual care £4467 18.110 – – –
TABLE 57 Sensitivity analysis applying intervention costs for a less-intensive intervention to increase physical
activity but assuming no reduction in efficacy
Intervention Mean cost Mean QALY Incremental cost Incremental QALY ICER
ERS £4448 18.216 £101.2 0.007 £14,503
Usual care £4346 18.209 – – –
TABLE 56 Sensitivity analysis applying the process utility gain estimated from Murphy et al.23 but limiting its
application to 1 year
Intervention Mean cost Mean QALY Incremental cost Incremental QALY ICER
ERS £4563 18.142 £217 0.026 £8290
Usual care £4346 18.115 – – –
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Conclusions
The ICER for the combined scenario analysis is £31,000 when using either the deterministic model or
the PSA output. The application of the ITT data increased the ICER largely because of its impact on the
absolute QALY gains, but this was more than counteracted by the assumption that process utility gain
would be accrued for up to 10 years with a linear fall-off in those remaining active being assumed.
The sensitivity analysis exploring the application of the EQ-5D utility data from the study by Murphy et al.23
shows that much larger QALY gains are estimated when applying the mean difference in utility between
study arms rather than attributing a process utility gain only to those who become active. However, it
should be noted that the EQ-5D difference measured by Murphy et al.23 was not statistically significant
and this uncertainty has not been captured in the results presented as there was insufficient time to run
the PSA for this sensitivity analysis. Furthermore, in our clinical effectiveness review, some but not all of the
studies that reported HRQoL data found a statistically significant difference between ERSs and usual care,
suggesting that this short-term benefit is still relatively uncertain.
The threshold analysis on intervention cost and the sensitivity analysis applying a lower cost of ERSs based
on the cost of a walking-based intervention, both demonstrate that the ICER is sensitive to the cost of
ERSs. It should be noted that these analyses assume that there is no relationship between the cost of the
scheme and its efficacy. It, therefore, cannot be concluded that lower-cost schemes are more cost-effective
unless it can also be shown that they are equally efficacious.
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